



The  
Patent  
Office

05/582761  
PCT/GB 98 / 03 9 1 8

30 DECEMBER 1998

INVESTOR IN PEOPLE

The Patent Office  
Concept House  
Cardiff Road  
Newport  
South Wales  
NP9 1RH

## PRIORITY DOCUMENT

SUBMITTED OR TRANSMITTED IN  
COMPLIANCE WITH RULE 17.1(a) OR (b)

REC'D 26 JAN 1999

WIPO

PC

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.

Signed

Dated

19 January 1999



Patents Form 1/77

Patent 1/77  
(Ru)

The  
Patent  
Office

02JAN98 E327772-1 D01631  
P01/7700 25.00 -9727512.7

Request for grant of a patent

(See the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form.)

The Patent Office

Cardiff Road  
Newport  
Gwent NP9 1RH

Fee: £25

1. Your reference 39162/JMD 31 DEC 1997

2. Patent application number  
(The Patent Office will fill in this part) 9727512.7

3. Full name, address and postcode of the or of each applicant (underline all surnames)  
AdProTech plc  
Unit 3, No. 2 Orchard Road,  
Royston,  
Herts. SG8 5HD.

Patents ADP number (if you know it)

If the applicant is a corporate body, give the country/state of incorporation  
United Kingdom

4. Title of the invention  
Fuzzy Genes and their Application in  
Improved Molecular Adjuvants

5. Full name, address and postcode in the United Kingdom to which all correspondence relating to this form and translation should be sent  
Reddie & Grose  
16 Theobalds Road  
LONDON  
WC1X 8PL

Patents ADP number (if you know it) 91001

6. If you are declaring priority from one or more earlier patent applications, give the country and the date of filing of the or of each of these earlier applications and (if you know it) the or each application number	Country	Priority application (If you know it)	Date of filing (day/month/year)

7. If this application is divided or otherwise derived from an earlier UK application, give the number and the filing date of the earlier application	Number of earlier application	Date of filing (day/month/year)


8. Is a statement of inventorship and of right to grant of a patent required in support of this request? (Answer 'Yes' if:

- a) any applicant named in part 3 is not an inventor, or
- b) there is an inventor who is not named as an applicant, or
- c) any named applicant is a corporate body.

See note (d)) YES

# Patents Form 1/77

9. Enter the number of sheets for any of the following items, not a filling with this form. Do not count copies of the same document.



Continuation sheets of this form

Description	59
Claim(s)	0
Abstract	0
Drawing(s)	0

10. If you are also filing any of the following, state how many against each item.

Priority documents	0
Translations of priority documents	0
Statement of inventorship and right to grant of a patent (Patents Form 7/77)	0
Request for preliminary examination and search (Patents Form 9/77)	0
Request for substantive examination (Patents Form 10/77)	0
Any other documents (please specify)	

11. I/We request the grant of a patent on the basis of this application.

Signature

Date

*James R Reddie Grose*

31 December 1997

12. Name and daytime telephone number of person to contact in the United Kingdom

J M DAVIES  
0171-242 0901

## Warning

After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or such direction has been revoked.

## Notes

- If you need help to fill in this form or you have any questions, please contact the Patent Office on 0645 500505.
- Write your answers in capital letters using black ink or you may type them.
- If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.
- If you have answered 'Yes' Patents Form 7/77 will need to be filed.
- Once you have filled in the form you must remember to sign and date it.
- For details of the fee and ways to pay please contact the Patent Office.

## **FUZZY GENES AND THEIR APPLICATION IN IMPROVED MOLECULAR ADJUVANTS**

This invention relates to novel genetic constructs designed to permit expression or synthesis of multidomain proteins containing extended repetitive sequences, particularly those useful for the creation of molecular adjuvants and immunogens.

The complement system consists of a set of serum proteins that are important in the response of the immune system to foreign antigens. The complement system becomes activated when its primary components are cleaved and the products, alone or with other proteins, activate additional complement proteins resulting in a proteolytic cascade. Activation of the complement system leads to a variety of responses including increased vascular permeability, chemotaxis of phagocytic cells, activation of inflammatory cells, opsonisation of foreign particles, direct killing of cells and tissue damage. Activation of the complement system may be triggered by antigen-antibody complexes (the classical pathway) or a normal slow activation may be amplified in the presence of cell walls of invading organisms such as bacteria and viruses (the alternative pathway). The complement system interacts with the cellular immune system through a specific pathway involving C3, a protein central to both classical and alternative pathways. The proteolytic activation of C3 gives rise to a large fragment (C3b) and exposes a chemically reactive internal thiolester linkage which can react covalently with external nucleophiles such as the cell surface proteins of invading organisms or foreign cells. As a result, the potential antigen is 'tagged' with C3b and remains attached to that protein as it undergoes further proteolysis firstly to iC3b and then to C3d,g & C3d. iC3b is a ligand for complement receptor CR3 and the latter fragments are ligands for CR2. Thus the labelling of antigen by C3b can result in a targeting mechanism for cells of the immune system bearing these receptors.

That such targeting is important for augmentation of the immune response is first shown by experiments in which mice were depleted of circulating C3 and then challenged with an antigen (sheep erythrocytes). Removal of C3 reduced the antibody

response to this antigen. (M.B. Pepys, J.Exp.Med, 140, 126-145, 1974). The role of C3 was confirmed by studies in animals genetically deficient in either C3 or the upstream components of the complement cascade which generate C3b, i.e. C2 and C4, (J.M. Ahearn & D.T. Fearon, Adv.Immunol. 46, 183-219, 1989). More recently, it has been shown that linear conjugation of a model antigen with more than two copies of the murine C3d fragment sequence resulted in a very large (1000-10000-fold) increase in antibody response in mice compared with unmodified antigen controls (P.W.Dempsey *et al*, Science, 271: 348-350, 1996; WO96/17625, PCT/GB95/02851). The increase could be produced without the use of conventional adjuvants such as Freund's complete adjuvant. The mechanism of this remarkable effect was demonstrated to be high-affinity binding of the multivalent C3d construct to CR2 on B-cells, followed by co-ligation of CR2 with another B-cell membrane protein, CD19 and with membrane-bound immunoglobulin to generate a signal to the B-cell nucleus.

In these experiments, the unmodified antigen control and linear fusions with one or two C3d domains were prepared by transfection of the appropriate coding plasmids into L cells followed by the selection of high-expressing clones. The most immunogenic construct, that with three C3d units, had to be expressed transiently in COS cells and this procedure gave a very poor yield of the fusion protein. In part, the low yield could be attributed to the generation of species containing the antigen but with lower molecular weights, corresponding to fewer than three C3d units. It was unclear from the published work of Dempsey *et al* whether the latter molecules originated by proteolysis of the three- C3d construct or whether they were due to a recombination event *in vivo*.

Using another expression system but the same C3d constructs as Dempsey *et al*, we have now obtained evidence that the generation of molecules with <3 C3d units from DNA encoding 3x C3d repeats is due to loss of one or more C3d units by homologous recombination and not due to post-translational processing (see below). This observation has also identified an efficient system for the expression of the C3d monomer.

It is known generally that the production of high molecular weight polypeptides containing multiple repeating sequences is difficult because of the tendency of repeated DNA sequences to undergo rearrangement during replication. Some of the limitations on internal repetitiveness in plasmids have been discussed by Gupta (Bio/Technology 1, 602-609, 1983). Ferrari *et al* ( US 5,641,648) have described methods for expression of repetitive sequences using synthetic genes constructed from monomeric units which are concatenated by ligation. DNA sequences encoding the same repeated amino acid sequence but differing in nucleotide sequence either within or between monomers were constructed by exploiting the redundancy of the genetic code. The resulting lack of precise repetitiveness at the nucleotide level reduced homologous recombination to the point where the repeated oligopeptide sequence could be expressed. The work of Ferrari *et al* was restricted to relatively short repeating units of 4 to 30 codons (amino-acids) repeated a large number of times (typically ~ 30-fold).

The present invention describes a general method for introducing maximum variability into entire genes or fragments of genes, particularly those encoding autonomously folding protein domains or motifs of >30 amino acids, in such a way that different DNA units encoding identical or near-identical amino acid sequences can be concatenated and expressed to give domain oligomers.

The invention comprises the following elements:

1. The construction of novel synthetic DNA sequences encoding an autonomously folding protein domain and using in these DNA sequences the maximum third-base redundancy in each codon permitted by the genetic code which is consistent with a continuous reading frame and retention of the amino acid sequence. These mixtures of DNA molecules are termed 'Fuzzy Genes'.
2. Assembling these genes into fuzzy or partially-fuzzy concatamers with or without in-frame coding regions for other proteins. 'Partially-fuzzy' means a construct in which some but not all regions of the DNA have third-base variability.

3. Placing this library of sequences into a suitable expression vector and expressing the population in a recombinant host cell.
4. The use of assays able to detect the presence of repeated-domain expressed protein products. Host cell clones are screened for those capable of producing useful levels of functionally active polypeptide concatamers / fusion proteins.
5. Characterising one or more unique DNA sequences derived from these clones and encoding the expressed product. Such DNA sequences will generally be novel as they have been selected from a highly diverse fuzzy-DNA pool.

In specific embodiments of the invention, the autonomously folding protein domain is a ligand for one or more cell surface receptors involved in the regulation of the immune system. One such example is human or murine C3d or C3d,g polypeptide sequence or another peptide ligand of CR2 (CD21) or CD19.

In a second embodiment, the repeated fuzzy or partially fuzzy domain may be an immunogen, particularly an antigenic protein or region of a protein. Examples of polypeptide immunogens include but are not restricted to: the Hepatitis B surface antigen, meningococcal surface proteins, proteins expressed at various stages of the life cycle of the malaria parasite, the glucan-binding region of streptococcal glucosyltransferases, the haemagglutinin (H) and neuraminidase (N) proteins of influenza virus strains and the D-repeat regions of the fibronectin binding proteins of staphylococci.

Optionally, an antigen oligomer may be fused to a C3d oligomer, either or both component being expressed from fuzzy or partially fuzzy genes.

In a third embodiment, the expressed oligomeric protein may be derivatised to facilitate post-translational linkage to an antigen or other protein. Preferably, such derivatisation is



effected by engineering a reactive residue such as a free cysteine or a thiolester group at a unique site in the oligomer, preferably at the C- or N-terminus.

In a further aspect, the invention also provides for expression of closely related polypeptides in a single linear molecule by the ligation of fuzzy DNA sequences encoding near-identical amino acid sequences. In this context, near-identical signifies sequences differing by at least one amino acid but not in more than 10% of the total number of amino acids. Examples of such constructs include but are not restricted to genes encoding several variations of a protein or antigen and concatenated immunoglobulin single-chain F<sub>v</sub> fragments with a similar overall architecture but containing small variations in the complementarity-determining regions so that they recognise different antigens.

Another embodiment of the invention utilises the novel DNA sequences identified by the selection process noted above as components of expression vectors for genetic (or DNA) immunisation. In this application, the preferred DNA sequences for expression in a given cell type (such as a human cell line) are identified by screening cells of that type transfected with a fuzzy or partially fuzzy DNA pool (within a suitable vector) for expression of the desired construct. This application may be further extended by chemically linking the expressed, derivatised C3d (or other protein) oligomers to DNA-binding molecules such as cationic lipids, lipopeptides or liposomes so that vectors for DNA immunisation may be targeted to particular cell types. Thus, for example, a C3d trimer linked to a liposome containing DNA encoding a (C3d)<sub>3</sub>-antigen fusion could be targeted to dendritic cells. Expression of the construct by the dendritic cells could then present a targeted antigen locally to further B-lineage cells thus achieving a dual-level selectivity.

The invention provides a process for preparing oligomeric polypeptides according to the invention which process comprises expressing DNA encoding said polypeptide in a recombinant host cell and recovering the product. That process may comprise the steps of:

- (i) preparing a variable (fuzzy) replicable expression vector capable, in a host cell, of expressing a DNA polymer comprising a nucleotide sequence that encodes said polypeptide;
- ii) transforming a host cell with said vector;
- iii) culturing said transformed host cell under conditions permitting expression of said DNA polymer to produce said polypeptide; and
- iv) recovering said polypeptide in an active form.

The fuzzy DNA polymer comprising a nucleotide sequence that encodes the polypeptide also forms part of the invention.

The process of the invention may be performed using conventional recombinant techniques such as described in Sambrook *et al.*, Molecular Cloning : A laboratory manual 2nd Edition. Cold Spring Harbor Laboratory Press (1989) and DNA Cloning vols I, II and III (D. M. Glover ed., IRL Press Ltd).

The invention also provides a process for preparing the DNA polymer by the condensation of appropriate mono-, di- or oligomeric nucleotide units.

The preparation may be carried out chemically, enzymatically, or by a combination of the two methods, *in vitro* or *in vivo* as appropriate. Thus, the DNA polymer may be prepared by the enzymatic ligation of appropriate DNA fragments, by conventional methods such as those described by D. M. Roberts *et al.*, in Biochemistry 1985, 24, 5090-5098.

The DNA fragments may be obtained by digestion of DNA containing the required sequences of nucleotides with appropriate restriction enzymes, by chemical synthesis, by enzymatic polymerisation, or by a combination of these methods.

Digestion with restriction enzymes may be performed in an appropriate buffer at a temperature of 20°-70°C, generally in a volume of 50µl or less with 0.1-10µg DNA. Enzymatic polymerisation of DNA may be carried out *in vitro* using a DNA polymerase such as DNA polymerase 1 (Klenow fragment) in an appropriate buffer containing the nucleoside triphosphates dATP, dCTP, dGTP and dTTP as required at a temperature of 10°-37°C, generally in a volume of 50µl or less. Enzymatic ligation of DNA fragments may be carried out using a DNA ligase such as T4 DNA ligase in an appropriate buffer at a temperature of 4°C to 37°C, generally in a volume of 50µl or less.

The chemical synthesis of the DNA polymer or fragments may be carried out by conventional phosphotriester, phosphite or phosphoramidite chemistry, using solid phase techniques such as those described in 'Chemical and Enzymatic Synthesis of Gene Fragments - A Laboratory Manual' (ed. H.G. Gassen and A. Lang), Verlag Chemie, Weinheim (1982), or in other scientific publications, for example M.J.Gait, H.W.D. Matthes M. Singh, B.S. Sproat and R.C. Titmas, *Nucleic Acids Research*, 1982, 10, 6243; B.S. Sproat and W. Bannwarth, *Tetrahedron Letters*, 1983, 24, 5771; M.D. Matteucci and M.H. Caruthers, *Tetrahedron Letters*, 1980, 21, 719; M.D. Matteucci and M.H. Caruthers, *Journal of the American Chemical Society*, 1981, 103, 3185; S.P. Adams *et al.*, *Journal of the American Chemical Society*, 1983, 105, 661; N.D. Sinha, J. Biernat, J. McMannus and H. Koester, *Nucleic Acids Research*, 1984, 12, 4539; and H.W.D. Matthes *et al.*, *EMBO Journal*, 1984, 3, 801. Preferably an automated DNA synthesiser (for example, Applied Biosystems 381A Synthesiser) is employed.

The DNA polymer is preferably prepared by ligating two or more DNA molecules which together comprise a DNA sequence encoding the polypeptide. The DNA molecules may be obtained by the digestion with suitable restriction enzymes of vectors carrying the required coding sequences.

The precise structure of the DNA molecules and the way in which they are obtained depends upon the structure of the desired product. The DNA molecule encoding the

polypeptide may be constructed using a variety of methods including chemical synthesis of DNA oligonucleotides, enzymatic polymerisation, restriction enzyme digestion and ligation. The derivation of a suitable strategy for construction of the DNA molecule by such techniques is a routine matter for the skilled worker in the art.

The systematic variation of third-base usage is described in more detail below (Example 3, Table 1) and additional consideration may be given to the avoidance of rarely used codons of the particular host cell.

The expression of the DNA polymer encoding the polypeptide in a recombinant host cell may be carried out by means of a replicable expression vector capable, in the host cell, of expressing the DNA polymer. The expression vector is novel and also forms part of the invention.

The replicable expression vector may be prepared in accordance with the invention, by cleaving a vector compatible with the host cell to provide a linear DNA segment having an intact replicon, and combining said linear segment with one or more DNA molecules which, together with said linear segment, encode the polypeptide, under ligating conditions.

The ligation of the linear segment and more than one DNA molecule may be carried out simultaneously or sequentially as desired. Thus, the DNA polymer may be preformed or formed during the construction of the vector, as desired. The choice of vector will be determined in part by the host cell, which may be prokaryotic, such as *E. coli*, mammalian, such as mouse C127, mouse myeloma, Chinese hamster ovary, or another eukaryote (e.g. filamentous fungi or unicellular yeast or an insect cell such as *Drosophila* or *Spodoptera*). The host cell may also be in a transgenic animal. Suitable vectors include plasmids, bacteriophages, cosmids and recombinant viruses derived from, for example, baculoviruses or vaccinia.

The DNA polymer may be assembled into vectors designed for isolation of stable transformed mammalian cell lines expressing the fragment e.g. bovine papillomavirus vectors in mouse C127 cells, or amplified vectors in Chinese hamster ovary cells (DNA Cloning Vol. II D.M. Glover ed. IRL Press 1985; Kaufman, R.J. *et al.* Molecular and Cellular Biology 5, 1750-1759, 1985; Pavlakis G.N. and Hamer, D.H. Proceedings of the National Academy of Sciences (USA) 80, 397-401, 1983; Goeddel, D.V. *et al.* European Patent Application No. 0093619, 1983).

The preparation of the replicable expression vector may be carried out conventionally with appropriate enzymes for restriction, polymerisation and ligation of the DNA, by procedures described in, for example, Sambrook *et al.*, cited above. Polymerisation and ligation may be performed as described above for the preparation of the DNA polymer. Digestion with restriction enzymes may be performed in an appropriate buffer at a temperature of 20°-70°C, generally in a volume of 50µl or less with 0.1-10µg DNA.

The recombinant host cell is prepared, in accordance with the invention, by transforming a host cell with a replicable expression vector of the invention under transforming conditions. Suitable transforming conditions are conventional and are described in, for example, Sambrook *et al.*, cited above, or "DNA Cloning" Vol. II, D.M. Glover ed., IRL Press Ltd, 1985.

The choice of transforming conditions is determined by the host cell. Thus, a bacterial host such as *E. coli*, may be treated with a solution of CaCl<sub>2</sub> (Cohen *et al.*, Proc. Nat. Acad. Sci., 1973, 69, 2110) or with a solution comprising a mixture of RbCl, MnCl<sub>2</sub>, potassium acetate and glycerol, and then with 3-[N-morpholino]-propane-sulphonic acid, RbCl and glycerol or by electroporation as for example described by Bio-Rad Laboratories, Richmond, California, USA, manufacturers of an electroporator. Eukaryotic cells in culture may be transformed by calcium co-precipitation of the vector DNA onto the cells or by using cationic liposomes.

The invention also extends to a host cell transformed with a variable replicable expression vector of the invention.

Culturing the transformed host cell under conditions permitting expression of the DNA polymer is carried out conventionally, as described in, for example, Sambrook *et al.*, and "DNA Cloning" cited above. Thus, preferably the cell is supplied with nutrient and cultured at a temperature below 45°C.

The protein product is recovered by conventional methods according to the host cell. Thus, where the host cell is bacterial such as *E. coli* and the protein is expressed intracellularly, it may be lysed physically, chemically or enzymatically and the protein product isolated from the resulting lysate. Where the host cell is eukaryotic, the product is usually isolated from the nutrient medium.

Where the host cell is bacterial, such as *E. coli*, the product obtained from the culture may require folding for optimum functional activity. This is most likely if the protein is expressed as inclusion bodies. There are a number of aspects of the isolation and folding process that are regarded as important. In particular, the polypeptide is preferably partially purified before folding, in order to minimise formation of aggregates with contaminating proteins and minimise misfolding of the polypeptide. Thus, the removal of contaminating *E. coli* proteins by specifically isolating the inclusion bodies and the subsequent additional purification prior to folding are important aspects of the procedure.

The folding process is carried out in such a way as to minimise aggregation of intermediate-folded states of the polypeptide. Thus, careful consideration needs to be given to, among others, the salt type and concentration, temperature, protein concentration, redox buffer concentrations and duration of folding. The exact condition for any given polypeptide generally cannot be predicted and must be determined by experiment.

There are numerous methods available for the folding of proteins from inclusion bodies and these are known to the skilled worker in this field. The methods generally involve breaking all the disulphide bonds in the inclusion body, for example with 50mM 2-mercaptoethanol, in the presence of a high concentration of denaturant such as 8M urea or 6M guanidine hydrochloride. The next step is to remove these agents to allow folding of the proteins to occur. Formation of the disulphide bridges requires an oxidising environment and this may be provided in a number of ways, for example by air, or by incorporating a suitable redox system, for example a mixture of reduced and oxidised glutathione.

Preferably, the inclusion body is solubilised using 8M urea, in the presence of mercaptoethanol, and protein is folded, after initial removal of contaminating proteins, by addition of cold buffer. A preferred buffer is 60mM ethanolamine containing 1mM reduced glutathione and 0.5mM oxidised glutathione. Ideally, the nature of the buffer is determined experimentally in order to obtain a protein product that is functionally active. The folding is preferably carried out at a temperature in the range 1 to 5°C over a period of 1 to 4 days.

If any precipitation or aggregation is observed, the aggregated protein can be removed in a number of ways, for example by centrifugation or by treatment with precipitants such as ammonium sulphate.

The polypeptide portion of the derivative of the invention may include a C-terminal cysteine to facilitate post-translational modification. Expression in a bacterial system is preferred for some proteins of moderate size (up to ~70kDa) and with <~8 disulphide bridges. More complex proteins for which a free terminal cysteine could cause refolding or stability problems may require expression in eukaryotic cells.

The use of insect cells infected with recombinant baculovirus encoding the polypeptide portion is a preferred general method for preparing more complex proteins, particularly the C3d oligomers of the invention.

A preferred method of handling proteins derivatised with cysteine is as a mixed disulphide with mercaptoethanol or glutathione or as the 2-nitro, 5-carboxyphenyl thio-derivative as generally described below.

Where the oligomeric polypeptide derivative of the invention includes a single cysteine, chemical ligation to a second polypeptide containing a unique cysteine may be employed. The bridge is generated by conventional disulphide exchange chemistry, by activating a thiol on one polypeptide and reacting the activated thiol with a free thiol on the other polypeptide. Such activation procedures make use of disulphides which form stable thiolate anions upon cleavage of the S-S linkage and include reagents such as 2,2'-dithiopyridine and 5,5'-dithiobis-(2-nitrobenzoic acid) (DTNB) that form intermediate mixed disulphides capable of further reaction with thiols to give stable disulphide linkages. One polypeptide activated in this way is then reacted with the second containing the free thiol. The precise conditions of pH, temperature, buffer and reaction time will depend on the nature of the reagent used and the polypeptide to be modified. The polypeptide linkage reaction is preferably carried out by mixing the modified polypeptides in neutral buffer in an approximately equimolar ratio. The reaction should preferably be carried out under an atmosphere of nitrogen. Preferably, UV-active products are produced (e.g. from the release of pyridine 2-thione from 2-pyridyl dithio derivatives) so that coupling can be monitored.

After the linkage reaction, the polypeptide conjugate can be isolated by a number of chromatographic procedures such as gel filtration, ion-exchange chromatography, affinity chromatography or hydrophobic interaction chromatography. These procedures may be either low pressure or high performance variants.

The conjugate may be characterised by a number of techniques including low pressure or high performance gel filtration, SDS polyacrylamide gel electrophoresis or isoelectric focussing.



In a further aspect, therefore, the invention provides a process for preparing a derivative according to the invention, this process comprises expressing DNA encoding the oligomeric polypeptide portion of said derivative in a recombinant host cell and recovering the product and thereafter post-translationally linking the polypeptide to a derivatised antigen or other polypeptide.

## GENERAL METHODS USED IN EXAMPLES

### (i) DNA Cleavage

Cleavage of DNA by restriction endonucleases was carried out according to the manufacturer's instructions using supplied buffers (New England Biolabs (U.K.) Ltd., Herts. or Promega Ltd., Hants, UK). Double digests were carried out simultaneously if the buffer conditions were suitable for both enzymes. Otherwise double digests were carried out sequentially where the enzyme requiring the lowest salt condition was added first to the digest. Once the digest was complete the salt concentration was altered and the second enzyme added.

### (ii) DNA ligation

Ligations were carried out using T4 DNA ligase purchased from Promega or New England Biolabs as described in Sambrook *et al*, (1989) Molecular Cloning: A Laboratory Manual 2nd Edition, Cold Spring Harbor Laboratory Press.

### (iii) Plasmid isolation

Plasmids were isolated using Wizard<sup>TM</sup> *Plus* Minipreps (Promega) or Qiex mini or midi kits and Qiagen Plasmid Maxi kit (QIAGEN, Surrey) according to the manufacturer's instructions.

Plasmid pSG.C3d<sub>1</sub>.YL encoding C3d monomer and plasmid pSG.(C3d)<sub>3</sub>.YL encoding C3d trimer were kindly provided by Professor D.T. Fearon, University of

Cambridge. All C3d constructs and their products derived from these plasmids are terminated with the epitope tag Glu-Glu-Phe.

**(iv) DNA fragment isolation**

DNA fragments were excised from agarose gels and DNA extracted using the QIAEX gel extraction kit or Qiaquick (QIAGEN, Surrey, UK), or GeneClean, or GeneClean Spin Kit or MERmaid Kit, or MERmaid Spin Kit (Bio 101 Inc, CA. USA) gel extraction kits according to the manufacturer's instructions.

**(v) Introduction of DNA into *E. coli***

Plasmids were transformed into competent *E. coli* BL21(DE3) or XL1-blue strains (Studier and Moffat, (1986), J. Mol. Biol. 189:113). The *E. coli* strains were purchased as a frozen competent cultures from Stratagene (Cambridge, UK).

**(vi) DNA sequencing**

The sequences were analysed by a Perkin Elmer ABI Prism 373 DNA Sequencer. This is an electrophoretic technique using 36 cm x 0.2mm 4% acrylamide gels, the fluorescently labeled DNA fragments being detected by a charge coupled device camera according to the manufacturer's instructions.

**(vii) Production of oligonucleotides**

Oligonucleotides were purchased from Cruachem, Glasgow, UK

**(viii) Generation of baculovirus vectors**

Plasmids described in this invention having the prefix pBP (e.g. pBP68-01 described below) are used to generate baculovirus vectors and express the encoded recombinant polypeptides by the following methods (Sections (viii) to (x)). Purified plasmid DNA was used to generate recombinant baculoviruses using the kit 'The BacPak Baculovirus Expression System' according to the manufacturer's protocols (Clontech, CA, USA). The insect cell line Sf9 (ATCC) was grown in IPL-41 medium

(Sigma, Dorset, UK) supplemented according to manufacturers recommendations with yeast extract, lipids and pluronic F68 (all from Sigma) and 1% (v/v) foetal calf serum (Gibco, Paisley, UK) - this is termed growth medium. Cells were transfected with the linearised baculovirus DNA (supplied in the kit) and the purified plasmid. Plaque assays (see method below) were carried out on culture supernatants and a series of ten-fold dilutions thereof to allow isolation of single plaques. Plaques were picked using glass Pasteur pipettes and transferred into 0.5ml aliquots of growth medium. This is the primary seed stock.

#### **(ix) Plaque assay of baculoviruses**

$1 \times 10^6$  Sf9 cells were seeded as monolayer cultures in 30mm plates and left to attach for at least 30 minutes. The medium was poured off and virus inoculum in 100 $\mu$ l growth medium was dripped onto the surface of the monolayer. The plates were incubated for 30 minutes at room temperature, occasionally tilting the plates to prevent the monolayer from drying out. The monolayer was overlaid with a mixture of 1ml growth medium and 3% (w/v) "Seaplaque" agarose (FMC, ME) warmed to 37°C and gently swirled to mix in the inoculum. Once set a liquid overlay of 1ml growth medium was applied. The plates were incubated in a humid environment for 3-5 days.

Visualisation of plaques was achieved by addition to the liquid overlay 1ml phosphate buffered saline (PBS) containing neutral red solution at 0.1% (w/v) from a stock solution of 1% (w/v) (Sigma, Dorset,UK). Plaques were visible as circular regions devoid of stain up to 3mm in diameter.

#### **(x) Scale-up of baculovirus vectors and protein expression**

200 $\mu$ l of the primary seed stock was used to infect  $1 \times 10^6$  Sf9 monolayer cell cultures in 30mm plates. The seed stock was dripped onto the monolayer and incubated for 20 minutes at room temperature, and then overlaid with 1ml growth medium. The plates were incubated at 27°C in a humid environment for 3-5 days. The supernatant from these cultures is Passage 1 virus stock. The virus titre was determined by plaque assay and further scale up was achieved by infection of monolayer cultures or suspension

cultures at a multiplicity of infection (moi) of 0.1. Virus stocks were passaged a maximum of six times to minimise the emergence of defective virus.

Expression of recombinant proteins was achieved by infection of monolayer or suspension cultures in growth medium with or without foetal calf serum (FCS). Where FCS was omitted cells conditioned to growth in the absence of FCS were used. Virus stocks between passage 1 and 6 were used to infect cultures at a moi of  $>5$  per cell. Typically, infected cultures were harvested 72 hours post infection and recombinant proteins isolated either from the supernatants or the cells.

**(xi) Selection of stable variants of (C3d)3 or other concatenated protein domains expressed in insect cells using baculovirus vectors**

Baculovirus transfer vector plasmids encoding uncharacterised C3d (or other protein domain) concatamers containing one or more fuzzy domains are transformed into competent *E.coli* XL1-blue strain according to Method (v). The resulting colonies each contain a single isolate which may be comprised of one or more fuzzy domains and may also contain one copy of the domain with the original DNA sequence derived from the parent plasmid (in the case of C3d, pSG.C3d.YL). Individual colonies are scaled up and DNA extracted according to Method (iii) (miniprep method). Aliquots of DNA are cotransfected into insect cells with BacPak6 linear DNA using a modification of the manufacturers protocol:  $2 \times 10^5$  Sf9 cells are seeded into flat-bottomed microtitre plates and allowed to attach for 30 minutes in serum free medium. If cells are grown in medium containing serum the monolayer is washed three times in serum free medium. The volume of medium in each well is adjusted to a standard volume (typically 50-150 $\mu$ l).

Each plasmid isolate 0.5 $\mu$ l of miniprep plasmid DNA was taken (at concentrations ranging from 0.5 to 5 $\mu$ g/ $\mu$ l) is mixed with 0.1 $\mu$ l to 2 $\mu$ l of BacPak6 DNA (Clontech) (at concentration supplied) and 5-25 $\mu$ l 50 $\mu$ g/ml of Lipofectin reagent (Life Technologies Inc.) and incubated at room temperature for 15 minutes to allow lipofectin/DNA complexes to form. The mixture is dripped onto the surface of the medium in a single microtitre well and swirled gently with the pipette tip. A single

microtitre dish may contain transfections of up to 96 plasmid isolates, one well per isolate. The transfections are incubated in a humid environment at 27°C for five hours.

The medium containing the Lipofectin/DNA is then removed from the monolayer and replaced with 100µl medium which may contain 1% FCS unless this is considered likely to interfere with subsequent assays. The plate is incubated in a humid environment at 27°C for three to five days. After three days the plate is visibly inspected for evidence of baculovirus infection. When a significant number of wells show signs of infection (retarded cell growth and enlarged or dumbbell-shaped cells) aliquots of culture supernatant are harvested from each well stored under sterile conditions for subsequent expansion. Further aliquots of culture supernatant or cells are subjected to biochemical or biological assay to determine the presence or absence of protein domain monomers and oligomers. For example, 20µl aliquots of supernatant may be subjected to SDS-PAGE and/or Western blotting (see Methods Section (xv) and (xvi)).

Selected clones showing significant yields of oligomers are scaled up from stored supernatants according to Method (x). Plasmids corresponding to the selected clones are also scaled up for large-scale plasmid DNA extraction according to Method (iii) and sequenced according to Method (vi).

#### (xii) pBROC413

The plasmid pT7-7 [Tabor, S (1990), Current Protocols in Molecular Biology, F. A. Ausubel, Brent, R. E. Kingston, D. D. Moore, J. G. Seidman, J. A. Smith, and K. Struhl, (eds). pp.16.2.1-16.2.11, Greene Publishing and Wiley-Interscience, New York.] contains DNA corresponding to nucleotides 2065-4362 of pBR322 and like pBR322 can be mobilised by a conjugative plasmid in the presence of a third plasmid ColK. A mobility protein encoded by ColK acts on the *nic* site at nucleotide 2254 of pBR322 initiating mobilization from this point. pT7-7 was digested with *Lsp*I and *Bgl*II and the protruding 5' ends filled in with the Klenow fragment of DNA Polymerase I. The plasmid DNA fragment was purified by agarose gel electrophoresis, the blunt ends ligated together and transformed into *E. coli* DH1 by electroporation using a Bio-Rad

Gene Pulser and following the manufacturers recommended conditions. The resultant plasmid pBROC413 was identified by restriction enzyme analysis of plasmid DNA.

The deletion in pBROC413 from the *LspI* site immediately upstream of the f 10 promoter to the *BglIII* site at nucleotide 434 of pT7-7 deletes the DNA corresponding to nucleotides 2065-2297 of pBR322. The *nic* site and adjacent sequences are therefore deleted making pBROC413 non mobilizable.

**(xiii) pDB1013**

The construction of this plasmid, a derivative of pBROC413, is fully described in Dodd *et al* (1995) Protein Expression and Purification 6: 727-736.

**(xiv) Protein Purification**

A number of standard chromatographic techniques can be used to isolate protein domain oligomers and fusions such as (C3d)<sub>3</sub> – for example, such methods as ion-exchange and hydrophobic interaction matrixes chromatography utilising the appropriate buffer systems and gradient to purify the target proteins. The chromatographic properties of the C3d or other domain-containing fusion polypeptides will vary depending on the nature of the fusion protein.

C3d molecules and derivatives constructed to contain the C-terminal affinity tag Glu-Glu-Phe can be purified by affinity chromatography using the YL1/2 antibody coupled to Sepharose 4B as described by Dempsey *et al* (WO 0617625; PCT/GB95/02851).

**(xv) Sodium Dodecyl Sulphate Polyacrylamide Gel Electrophoresis (SDS-PAGE)**

SDS-PAGE was carried out generally using the Novex system (Novex GmbH, Heidelberg) according to the manufacturer's instructions. Pre-packed gels of containing a 4- 20% acrylamide gradient were used. Samples for electrophoresis, including protein molecular weight standards (for example LMW Kit, Pharmacia, Sweden or Novex Mark 12, Novex, Germany) were usually diluted 1:1 in 2% (w/v) SDS - containing buffer (with

or without 5% (v/v) 2-mercaptoethanol), and left at room temperature for 0.5h before application to the gel.

#### **(xvi) Immunoblotting**

##### **(a) Dot blot**

Immobilon membranes (Millipore, Middlesex, UK) were activated by immersion in methanol for 20 seconds and then washed in PBS for five minutes. The membrane was placed into a vacuum manifold Dot Blotter (Bio-Rad Laboratories, Watford, UK). Crude extracts from cells or culture supernatants were transferred onto the membrane by applying a vacuum and washed through with PBS. Without allowing the membrane to dry out, the Dot Blotter was dismantled and the membrane removed.

##### **(b) Western Blotting**

Samples of cell extracts and purified proteins were separated on SDS-PAGE as described in Section (xv). The Immobilon membrane was prepared for use as in (a) above. The gel and the membrane were assembled in the Semi-Dry Transfer Cell (Trans-Blot SD, Bio-Rad Laboratories) with the Immobilon membrane towards the anode and the SDS-PAGE on the cathode side. Between the cathode and the gel were placed 3 sheets of Whatman 3M filter paper cut to the size of the gel pre-soaked in a solution of 192mM 6-amino-n-caproic acid, 25mM Tris pH 9.4 containing 10% (v/v) methanol. Between the anode and the membrane were placed two sheets of Whatman 3M filter paper cut to the size of the gel and soaked in 0.3M Tris pH 10.4 containing 10% (v/v) methanol next to the anode and on this was laid a further sheet of Whatman 3M filter paper pre-soaked in 25mM Tris pH 10.4 containing 10% (v/v) methanol.

The whole-assembled gel assembly was constructed to ensure the exclusion of air pockets. The proteins were transferred from the SDS-PAGE to the Immobilon membrane by passing 200mA current through the assembly for 30 minutes.

##### **(c) Immunoprobng of Dot Blot and Western Membranes**

The membranes were blocked by incubating the membrane for 1h at room temperature in 50ml of 10mM phosphate buffer pH 7.4 containing 150mM NaCl, 0.02%

(w/v) Ficoll 400, 0.02% (w/v) polyvinylpyrrolidone and 0.1% (w/v) bovine serum albumin (BSA). The appropriate primary antibody was diluted to its working concentration in antibody diluent, 20mM sodium phosphate buffer pH 7.4 containing 0.3M NaCl, 0.5% (v/v) Tween-80 and 1.0% (w/v) BSA. The membrane was incubated for 2h at room temperature in 50ml of this solution and subsequently washed three times for 2 minutes in washing buffer, 20mM sodium phosphate pH 7.4 containing 0.3M NaCl and 0.5% (v/v) Tween-80. The membrane was then transferred to 50ml of antibody diluent buffer containing a suitable dilution of the species specific antibody labelled with the appropriate label, e.g. biotin, horse radish peroxidase (HRP), for the development process chosen and incubated for 2h at room temperature. The membrane was then washed in washing buffer as described above. Finally, the blot was developed according to the manufacturer's instructions.

The appropriate dilution of antibody for both the primary and secondary antibodies refers to the dilution that minimises unwanted background noise without affecting detection of the chosen antigen using the development system chosen. This dilution is determined empirically for each antibody.

#### **(xvii) Measurement of Biological Activity**

The biological function of C3d monomer produced in baculovirus can be tested for its ability to bind to its receptor, complement receptor-2 (CR2). As C3d is a product of the process of complement activation and subsequent degradation of C3b by the serum protease Factor I, it was also of interest to test C3d for its possible effect on complement activation using a classical pathway haemolytic assay.

#### **(a) Competitive Binding Assay of C3d to Raji Cells**

In this assay the ability of a new construct expressing at least one unit of C3d to compete with a control  $^{125}\text{I}$ -HEL-C3d for CR2 binding sites on the surface of Raji cells, a B-lymphoblastoid cell line, is assessed. Raji cells,  $5 \times 10^7$  to  $7 \times 10^7$  cells/ml are incubated for 1h at  $4^\circ\text{C}$  with  $1\text{nM}$   $^{125}\text{I}$ -HEL-C3d and incremental concentrations of C3d containing molecule of interest. The cells are then centrifuged through a dibutyl-diiso-octyl-phthalate cushion, and the amount of radioactivity associated with the pellet determined.



From this data the amount of the C3d-containing protein under test necessary to produce a 50% reduction in 1nM  $^{125}$ I-HEL-C3d can be determined.

**(b) Competitive ELISA demonstrating C3d Binding to CR2**

C3d is used to coat 96-well microtitre plates at 5 $\mu$ g/ml in 0.1M NaHCO<sub>3</sub> by incubating overnight at 4°C. The plates are then blocked in 1% BSA, 0.1% Tween-20 in PBS for 1h at room temperature and subsequently incubated with either 25 $\mu$ l/well of C3d or variable test volumes of the C3d-containing molecule of interest to generate a dose response. To the wells is added 25 $\mu$ l/well of a sub-saturating concentration of co-ligated CR2.IgG1 at 125pM and incubated for 1h at room temperature. The plates are then washed three times with PBS containing 0.1% (v/v) Tween-20. The amount of CR2 bound to the immobilised C3d is detected using a 1:3000 dilution of HRP-labeled goat anti-mouse-IgG1-antibody in PBS containing 0.1% (v/v) Tween-20 and incubated for 1h at room temperature the wells were then washed as described above. The presence of HRP-antibody is detected using the TMB Peroxidase EIA Substrate Kit according to the manufacturer's instructions (Bio-Rad, UK).

**(c) Anti-complement Activity Measured by the Haemolysis of Sheep Erythrocytes**

Measuring the inhibition of complement-mediated lysis of sheep erythrocytes sensitised with rabbit antibodies (Diamedix Corporation, FL, USA) assesses functional activity of complement inhibitors. Human serum diluted 1:125 or 1:100 in 0.1 M HEPES/0.15 M NaCl/0.1% gelatin pH 7.4 was used as a source of complement. The serum was pooled from volunteer blood donations essentially as described in J.V.Dacie & S.M. Lewis, *Practical Haematology*, Churchill Livingstone, Edinburgh. 1975. Briefly, blood (10-20ml) was warmed to 37°C for 5 minutes, the clot removed and the remaining serum clarified by centrifugation. The serum fraction was split into small aliquots and stored at -196°C. Aliquots were thawed as required and diluted in the HEPES buffer immediately before use.

Inhibition of complement-mediated lysis of sensitised sheep erythrocytes is measured using a standard haemolytic assay using a v-bottom microtitre plate format as follows:

50µl of a range of concentrations of inhibitor (typically in the region of 0.1-100 nM) diluted in HEPES buffer are mixed with 50µl of the diluted serum and 100µl of sensitised sheep erythrocytes and then incubated for 1 hour at 37°C. Samples are spun at 1600rpm at ambient temperature for 3 minutes before transferring 150µl of supernatant to flat bottom microtitre plates and determining the absorption at 410nm. Maximum lysis (A<sub>max</sub>) is determined by incubating serum with erythrocytes in the absence of any inhibitor. Background lysis (A<sub>o</sub>) is determined by incubating erythrocytes in the absence of any serum or inhibitor to check whether the inhibitor itself had any effect on lysis, erythrocytes were incubated with inhibitor alone; none of the compounds had any direct effect on lysis of the erythrocytes. Inhibition is expressed as a fraction of the total cell lysis such that IH50 represents the concentration of inhibitor required to give 50% inhibition of lysis.

$$IH = \frac{A - A_o}{A_{max} - A_o}$$

where 0 is equivalent to complete inhibition and 1 equals no inhibition.

#### **(xviii) Reduction of disulphides and modification of thiols in proteins**

There are a number of methods used for achieving the title goals. The reasons it may be necessary to carry out selective reduction of disulphides is that during the isolation and purification of multi-thiol proteins, in particular during refolding of fully denatured multi-thiol proteins, inappropriate disulphide pairing can occur. In addition, even if correct disulphide pairing does occur, it is possible that a free cysteine in the protein may become blocked, for example with glutathione. These derivatives are generally quite stable. In order to make them more reactive, for example for subsequent conjugation to another functional group, they need to be selectively reduced, with for example dithiothreitol (DTT) or with Tris (2-carboxyethyl) phosphine.HCl (TCEP) then optionally modified with a function which is moderately unstable. An example of the latter is Ellman's reagent (DTNB) which gives a mixed disulphide. In the case where treatment with DTNB is omitted, careful attention to experimental design is necessary to ensure that dimerisation of the free thiol-containing protein is minimised. Reference to the term 'selectively reduced' above means that reaction conditions eg. duration,

temperature, molar ratios of reactants have to be carefully controlled so that disulphide bridges within the natural architecture of the protein are not reduced. All the reagents are commercially available e.g. from Sigma (Poole, Dorset) or Pierce & Warriner (Chester, Cheshire).

The following general examples illustrate the type of conditions that may be used and that are useful for the generation of free thiols and their optional modification. The specific reaction conditions to achieve optimal thiol reduction and/or modification are ideally determined for each protein batch.

TCEP may be prepared as a 20mM solution in 50mM HEPES (approx. pH 4.5) and may be stored at -40°C. DTT may be prepared at 10mM in sodium phosphate pH 7.0 and may be stored at -40°C. DTNB may be prepared at 10mM in sodium phosphate pH 7.0 and may be stored at -40°C. All of the above reagents are typically used at molar equivalence or molar excess, the precise concentrations ideally identified experimentally. The duration and the temperature of the reaction are similarly determined experimentally. Generally the duration would be in the range 1 to 24 hours and the temperature would be in the range 2 to 30°C. Excess reagent may be conveniently removed by buffer exchange, for example using Sephadex G25. A suitable buffer is 0.1M sodium phosphate pH 7.0.

## EXAMPLES

**Example 1. Expression and isolation of monomeric murine C3d [(C3d)1] (SEQ ID No 26) and trimeric C3d [(C3d)3] (SEQ ID No. 27) in *Escherichia coli* – Evidence for instability of the trimeric construct in a bacterial host.**

### (a) Construction of plasmid pDB1033 encoding (C3d)1

pDB1013 was digested with *SpeI* / *NdeI* and the vector fragment was isolated from a 1.1% (w/v) agarose gel and purified using a Qiagen gel extraction kit.

The vector termed pSG.C3d<sub>1</sub>.YL described in patent WO 96/17625 encodes one copy of the C3d coding sequence preceded by a signal peptide derived from dog pre-pro-insulin and is C-terminally tagged by the tripeptide epitope (Glu-Glu-Phe) recognised by the commercially available YL1/2 antibody (Serotec, Oxon). The vector was cut with *Bgl*II and *Xba*I; the digest was run on a 1.1% (w/v) agarose gel and the 1000 base pairs *Bgl*II / *Xba*I fragment isolated.

These two fragments were ligated with the *Bgl*II / *Nde*I linkers (SEQ ID Nos 28 and 29) and transformed into competent *E. coli* JM109 cells under standard conditions and clones isolated.

**(b) Expression of (C3d)<sub>1</sub> from pDB1033**

pDB1033 was transformed into calcium chloride competent *E. coli* BL21(DE3) and resultant colonies were isolated and checked for plasmid content. To express protein from pDB1033 in *E. coli* BL21(DE3), a single colony was inoculated into 10ml LB media (20g/l tryptone, 15g/l yeast extract, 0.8g/l NaCl, 0.2g/l Na<sub>2</sub>HPO<sub>4</sub>, 0.1g/l KH<sub>2</sub>PO<sub>4</sub>) containing 50µg/ml ampicillin (Sigma). The culture was grown for 6 hours at 37°C, 260rpm before being used to inoculate 100ml of the same media containing 50µg/ml ampicillin. Growth was under the same conditions overnight. 25ml of each culture was then used to inoculate 3 x 500ml of the same media with 50µg/ml ampicillin in 3l Erlenmeyer flasks. Cells were grown to an OD of about 1.2 at A<sub>600nm</sub>. IPTG (isopropyl β-D galactopyranoside) was added to a final concentration of 1mM and cells incubated for a further about 3.5 hours before harvesting by centrifugation at 8000g/10 minutes. Cell pellet from 1.5l of culture was processed immediately.

**(c) Isolation of (C3d)<sub>1</sub>**

The methods described are essentially those detailed for the isolation of SCR1-3 of Complement Receptor 1 in Dodd. *et al* (1995) Protein Expression and Purification 6: 727-736, with some modifications.

**(i) Isolation of solubilised inclusion bodies**

The cell pellet of *E. coli* BL21(DE3) (pDB1033) was resuspended in 50mM Tris/50mM NaCl/ 1mM EDTA pH 8.0 (approximately 150ml). The suspension was transferred to a glass beaker surrounded by ice and sonicated (Heat systems - Ultrasonics W380; 50 x 50% pulse, pulse time = 5 seconds.) for 3 minutes and then spun at 15000g for 10 minutes. The supernatant was decanted and discarded. The inclusion body pellet was stored at -40°C for 7 days. It was then resuspended in 20mM Tris/8M urea/1mM EDTA/50mM 2-mercaptoethanol pH 8.5 (120ml) at room temperature by vigorous swirling, then left for 2 hours at room temperature with occasional swirling.

**(ii) Initial purification using Macroprep High Q**

To the viscous solution was added Macroprep High Q (Bio-Rad; 24g wet weight) that had been water washed and suction-dried. The mixture was swirled vigorously and left static for 1-2h at room temperature. The supernatant was decanted, sampled and discarded. The remaining slurry was resuspended to a uniform suspension and poured into a glass jacket and allowed to settle into a packed bed. The column was equilibrated with 0.02M Tris/8M urea/0.05M 2-mercaptoethanol/0.001M EDTA pH 8.5 at room temperature. When the A<sub>280</sub> of the eluate had stabilised at baseline, the buffer was changed to equilibration buffer additionally containing 1M NaCl. A single A<sub>280</sub> peak was eluted by the 1M NaCl-containing buffer; the volume was approximately 80ml. SDS-PAGE under reducing conditions showed the product contained one major species, with a molecular weight around 35000. The solution was stored at -40°C.

**(d) Construction of plasmid pDB1032 encoding (C3d)<sub>3</sub>**

pDB1013 was digested with *SpeI* / *NdeI* and the vector fragment isolated from a 1.1% (v/w) agarose gel and purified using a Qiagen gel extraction kit.

The vector termed pSG.(C3d)<sub>3</sub> YL described in patent WO 96/17625 encodes three identical copies of the C3d coding sequence preceded by a signal peptide derived from dog pre-pro-insulin. The C3d domains are separated by a linker (Gly<sub>4</sub>-Ser)<sub>2</sub>, and there is tripeptide epitope (Glu-Glu-Phe) at the C-terminal of the final C3d domain that is

recognised by the commercially available YL1/2 antibody (Serotec, Oxon.). The vector was cut with *Bgl*III and *Xba*I; the digest was run on a 1.1% (v/w) agarose gel and the 3000 base pairs *Bgl*III / *Xba*I fragment isolated. These two fragments were ligated with the *Bgl*III / *Nde*I linkers (SEQ ID Nos 28 and 29) and transformed into competent *E. coli* JM109 cells under standard conditions and clones containing pDB1032 were isolated.

**(b) Expression of (C3d)3 from pDB1032**

pDB1032 was transformed into calcium chloride competent *E. coli* BL21(DE3) and resultant colonies were isolated and checked for plasmid content. To express protein from pDB1032 in *E. coli* BL21(DE3), a single colony was inoculated into 10ml LB-phosphate (20g/l tryptone, 15g/l yeast extract, 0.8g/l NaCl, 0.2g/l Na<sub>2</sub>HPO<sub>4</sub>, 0.1g/l KH<sub>2</sub>PO<sub>4</sub>) containing 50µg/ml ampicillin. The culture was grown overnight at 37°C, 230rpm. before being used to inoculate 50ml of the same medium containing 50µg/ml ampicillin. Growth was under the same conditions overnight. 15ml of each culture was then used to inoculate 3 x 600ml of the same medium with 50µg/ml ampicillin in 3l Erlenmeyer flasks. Cells were grown to an OD of about 1.1 at A<sub>600nm</sub>. IPTG was added to a final concentration of 1mM and cells allowed to continue growth for a further about 3.5 hours before harvesting by centrifugation at 8000g/10 minutes. Pellet from 1.5l of culture was processed immediately.

**(c) Isolation of (C3d)3**

The methods described are essentially those detailed for the isolation of SCR1-3 of Complement Receptor 1 in Dodd *et al* (1995) Protein Expression and Purification 6: 727-736, with some modifications.

**(i) Isolation of solubilised inclusion bodies**

The cell pellet of *E. coli* BL21(DE3) (pDB1032) was resuspended in 50mM Tris/50mM NaCl/1mM EDTA pH 8.0/0.1mM PMSF (approx. 100ml). The suspension was transferred to a glass beaker surrounded by ice and sonicated (Heat systems - Ultrasonics W380; 50 x 50% pulse, pulse time = 5 seconds.) for 3 minutes and then spun at 15000g for 10 minutes. The supernatant was decanted and discarded. The inclusion

body pellet was stored at  $-40^{\circ}\text{C}$  for 3d. It was then resuspended in 20mM Tris/8M urea/1mM EDTA/50mM 2-mercaptoethanol pH 8.5 (120ml) at room temperature by vigorous swirling, then left for 2h at room temperature with occasional swirling.

**(ii) Initial purification using Macroprep High Q**

To the viscous solution was added Macroprep High Q (Bio-Rad; 24g wet weight) that had been water washed and suction-dried. The mixture was swirled vigorously and left static for 1-2h at room temperature. The supernatant was decanted, sampled and discarded. The remaining slurry was resuspended to a uniform suspension and poured into a glass jacket and allowed to settle into a packed bed. The column was equilibrated with 0.02M Tris/8M urea/0.05M 2-mercaptoethanol/0.001 M EDTA pH 8.5 at room temperature. When the  $A_{280}$  of the eluate had stabilised at baseline, the buffer was changed to equilibration buffer additionally containing 1M NaCl. A single  $A_{280}$  peak was eluted by the 1M NaCl-containing buffer; the volume was approximately 80ml. SDS PAGE under reducing conditions showed that the product contained one major species, with a molecular weight around 35000, and additional species with molecular weights close to the target molecular weight of around 105000 and believed to be the target species. The solution was stored at  $-40^{\circ}\text{C}$ .

These results show that expression in a bacterial host of either monomeric or trimeric C3d genes gives rise to substantially the same product – the monomeric protein. The origins of this instability were not determined in this experiment.

**Example 2. Expression and isolation of C3d oligomers expressed in insect cells using baculovirus vectors: Evidence for homologous recombination as the origin of the low yield of trimer and the high yield of a monomeric C3d form.**

**(a) Construction of plasmid pBC68-01 encoding (C3d)<sub>3</sub>-EEF**

The vector termed pSG.(C3d)<sub>3</sub> YL described in patent WO 96/17625 encodes three identical copies of the C3d coding sequence preceded by a signal peptide derived

from dog pre-pro-insulin. The C3d domains are separated by a linker (Gly<sub>4</sub>-Ser)<sub>2</sub>, and there is tripeptide epitope (Glu-Glu-Phe) at the C-terminal of the final C3d domain that is recognised by the commercially available YL1/2 antibody (Scrotec, Oxon.)

pSG.(C3d)<sub>3</sub>-YL was digested with restriction endonucleases *Eco*RI and *Xba*I and the 3075 base pairs band was isolated from an 1% (w/v) agarose gel using GeneClean extraction kit according to the manufacturer's instructions. The baculovirus expression vector pBacPak8 (Clontech) was digested with restriction endonucleases *Eco*RI and *Xba*I and the 5.6k base pairs band was isolated from a 0.7% (w/v) agarose gel.

The two fragments were ligated with T4 DNA ligase to give pBP68-01. The ligated plasmid was transformed into competent *E. coli* XL1-blue purchased from Stratagene. Ampicillin resistant transformants were selected on LB-agar plates containing 50µg/ml ampicillin. Resulting colonies were analysed by restriction endonuclease digestion. Plasmid DNA was extracted from *E. coli* containing pBP68-01 using Qiaex mini or midi prep kits according to manufacturer's protocols.

#### **b) Generation of baculovirus vBP68-01 for expression of C3d oligomers**

Purified pBP68-01 plasmid DNA was used to generate a recombinant baculovirus expression vector for (C3d)<sub>3</sub>-YL as described in General Methodology Section (viii). Resulting plaques were picked and used to generate primary seed stocks. Recombinant baculoviruses expressing C3d oligomers were identified by immuno-dot blot of culture supernatants of Passage 1 virus stocks, probing with an antibody to human C3d obtained from Dako (Ely, Cambs) at a dilution of 1 in 2000 the blot was developed using the ECL kit (Amersham, Middlesex). Those showing a positive signal on the dot blot were further scaled up and used to generate Passage 3 or 4 working stocks with virus titres between 10<sup>7</sup> and 10<sup>9</sup> plaque forming units (pfu) per ml.

#### **(c) Expression of C3d oligomers in insect cells**

Sf9 cells adapted for growth in the absence of serum were grown in suspension culture to a cell density of 1.5x10<sup>6</sup> cells/ml in 4x50ml of media in 200ml Erlenmeyer flasks shaken at 20rpm. These cells were then infected by addition of 1x10<sup>9</sup> pfu/ml Passage 3 working stocks to give a final concentration of 5pfu/cell. The supernatant 72



hours post infection was found to contain three species of C3d oligomer: (C3d)<sub>3</sub>, as encoded in the original vector, in trace amounts, (C3d)<sub>2</sub>, also in trace amounts and C3d monomer relatively large amounts (5-10mg/l). The harvest medium, 210ml, was stored at -40°C until further processed.

**(d) Purification of C3d from Sf9 Baculovirus Harvest Media**

Approximately half the harvest supernatant, 113ml, was adjusted to pH 7.4 with 10M NaOH and the conductivity of the solution measured usually the salt concentration was below 0.1M if it was above this concentration the solution was diluted with the appropriate amount of 50mM HEPES pH 7.4 to bring the salt concentration to 80mM.

The harvest supernatant was loaded onto a Macrorep-high-Q column, bed volume; 25ml pre equilibrated in 50mM HEPES pH 7.4 and then washed with 50mM HEPES pH 7.4 until the baseline stabilised. The linear flow rate for loading and washing the column was 89cm/h and was decreased to 60cm/h during elution. The bound proteins were eluted with a linear 0-1M NaCl over 10 column volumes and 5ml fractions collected. The column material was heavily contaminated with medium components and was discarded after a single use.

The C3d eluted between 0.15M and 0.3M NaCl as revealed by reducing SDS-PAGE. The fractions eluting between 0.15M NaCl and 0.2M NaCl were 50% pure, (C3d)<sub>2</sub> and (C3d)<sub>3</sub> eluted after the C3d<sub>1</sub>. The C3d<sub>1</sub> pooled fractions, 40ml, were concentrated to 2ml by using 40ml ultrafiltration stirred cell containing a YM10 membrane (Amicon, Glos.). No further purification was performed prior to characterisation of the product -see Sections (e) and (f) below.

**(e) Physiochemical Characterisation of the monomeric species**

**(i) N-Terminal Sequence**

A sample containing the monomeric C3d was separated on a reducing SDS-PAGE. The proteins were electro-transferred to a Problott (Applied Biosystems) as described in General Methods (Section (xvi) (b)). Post electrotransfer the membrane was rinsed in 100% methanol for 10s and then stained with a solution containing 0.1% (w/v) amido black (Sigma), 40% methanol, 1% acetic acid for 30s and subsequently

destained by a 50% methanol solution. The band corresponding to the C3d monomer was excised. The N-terminal sequence of the protein was analysed by Edman Degradation using a Beckman Automatic Amino Acid Analyser (Beckman). A single N-terminal sequence was obtained, this sequence corresponded to residues 25 to 44 of the C3d1 sequence expressed in Baculovirus/Sf9 cells (SEQ ID. No.37) and indicated that the secreted monomer had its signal sequence removed.

**(ii) Mass Spectrometry.**

The mass of the C3d was determined by electrospray mass spectrometry on a solution containing the purified C3d. A single peak was found with a mass of 34279 Da. This corresponds to a sequence starting at the N-terminal sequence as described in Section (d) (i) above but containing the C-terminal antibody affinity tag (Glu-Glu-Phe). This sequence shown below (SEQ ID no.37).

**(iii) Western Blotting**

The purified C3d was western blotted according to the methods described in Section (xvi) (b) following separation on a reducing SDS-PAGE. The blot was probed with primary antibodies to C3d and the affinity tag Glu-Glu-Phe.

**(1) C3d Antibody** Primary rabbit polyclonal antibody to human C3d (Dako, Cambs. UK) and the secondary antibody a biotin-labelled polyclonal goat anti-rabbit IgG antibody (Amersham, Bucks.) were used at 1: 500 dilution of the stock. The blot was developed using the Immunogold Silver Staining Kit (Amersham) according to the manufacturer's instructions. The developed blot showed a single immunoreactive band corresponding to the correct position of the C3d monomer on the SDS-PAGE.

**(2) Antibody to Affinity Tag.** Monoclonal rat antibody from clone YL1/2 (Serotec) recognising the C-terminal tag Glu-Glu-Phe was used a 1:500 dilution to probe the immunoblot. The secondary antibody biotin-labelled polyclonal goat anti-rat antibody was used at a dilution of 1:1000. The blot was developed using the Immunogold Silver Staining Kit (Amersham, UK) according to the manufacturer's instructions. The developed blot showed a single immunoreactive band corresponding to the correct position of the C3d monomer on the SDS-PAGE. This result indicated the presence of

the epitope tag in a major proportion of the C3d monomers.

These Sections (i to iii) suggest the C3d expressed in harvest supernatant contains the N-terminal of the first C3d unit containing the signal sequence encoded in the plasmid pBP68-01 and the C-terminal of the molecule the information encoded by the third unit of C3d containing the affinity tag in the plasmid. The amino acid sequence of this combination is described in SEQ ID no. 37.

**(f) Biological Assay of the C3d monomer**

The biological function of C3d monomer produced in baculovirus was tested by its ability to bind to its receptor, complement receptor-2 (CR2).

**(i) Competitive Binding Assay of C3d to Raji Cells**

The binding was performed as described in General Methods Section (xvii) (a). The amount of radioactivity associated with the cell pellet was used to construct a binding curve of  $^{125}\text{I}$ -HEL-C3d bound to the Raji cells, this showed a 50% reduction in binding of the label was achieved using of binding concentration of  $2.5\mu\text{M}$  of either the baculovirus /Sf9 C3d or C3d expressed in COS cells.

**(ii) ELISA demonstrating C3d Binding to CR2**

The ELISA was performed as described in General Methods Section (xvii) (b). The monomer gave a  $I_{50}$  of  $2\mu\text{M}$  for the baculovirus/Sf9 material. A similar figure was obtained for the COS cell produced C3d.

**(iii) Anti Haemolytic Activity of C3d**

The anti-haemolytic assay was performed as described in the General Methods Section (xvii) (c) on a purified sample of C3d1. The C3d1 protein product inhibited complement-mediated lysis of sensitised sheep red blood cells with an  $\text{IH}_{50}$  of approximately  $700\text{nM}$ . The C3d activity in this assay is probably as a competitive inhibitor of C3 the complement pathway.

The data described in this Section provides evidence that C3d produced in the baculovirus/Sf9 expression system is equivalent in activity to that produced in COS cells. However this system produces at least 50-fold more C3d per litre than the COS system offering significant fermentation savings.

**(g) Characterisation of baculovirus vector produced from pBP68-01.**

Characterisation of the monomeric protein led to the hypothesis that homologous recombination had occurred within the repeated C3d coding sequence in the baculovirus vector leading to deletion of two copies of C3d. PCR analysis was used to characterise the viruses present in the cultures, which produced the monomeric species.

DNA was extracted from the cell pellets from 50ml samples from two independent production runs. The cells were suspended in 5ml of a solution containing 10mM Tris, 10mM EDTA, 100µg/ml proteinase K pH 7.6. After re-suspension SDS was added to 0.5% (w/v), mixed gently to avoid shearing the DNA and incubated for 60 minutes at 37°C. An equal volume of phenol: chloroform: isoamyl alcohol, 1:24:1, (Sigma) was added and mixed by inversion for 5 minutes then centrifuged at 12000g for 5 minutes. The upper aqueous layer was transferred to a clean tube and a 0.6 volume of isopropanol was added to precipitate the DNA. A clot of DNA was produced which was transferred into 5ml 80% (v/v) ethanol for 1 minute. The ethanol was poured off and drained without allowing the pellet DNA clot to dry completely. The DNA clot was dissolved in 1ml deionised water containing 50 units of RNase A (Sigma).

A PCR reaction was carried out to determine the length of the DNA encoding C3d. The primers used for the PCR were homologous to sequences flanking the coding region, corresponding to the position of the *Eco*RI and *Xba*I restriction sites used in the cloning. The sequence of the forward primer #39171 was GAATTCCTAGCTTGCTTG (SEQ. ID No 30) and the reverse primer #39172 was TCTAGAGTCGACCAGAC (SEQ. ID No.31). The PCR conditions were as follows: 1µl DNA solution (from cell pellets), 1µl 10mM dNTPs, 50pMol each of forward and reverse primers (SEQ. ID no. 30 and 31), 5µl x10 Taq polymerase buffer (Promega), 3µl 25mM MgCl<sub>2</sub>, deionised water to 49µl and 1µl Taq polymerase (5 units) (Promega). PCR was carried out in a thermal cycler

with the following cycle: Step 1: 95°C for 1 minute, Step 2: 95°C for 30 seconds, Step 3: 55°C for 30 seconds, Step 4: 72°C for 1 minute, Step 5: 72°C for 5 minutes. Steps 2-4 were repeated 30 times prior to step 5. A tenth of the products were run on 1% (w/v) agarose gels. The expected size for (C3d)<sub>3</sub> was 3088 base pairs and for C3d monomer was 1217 base pairs. The PCR product of the reactions was clearly a 1217 base pairs band with no evidence of a 3088 base pairs band.

These data, and the protein characterisation data strongly suggest that a homologous recombination event has occurred resulting in the deletion of two of the three C3d genes, leaving the signal peptide and the amino terminal portion of the first domain and the carboxy terminal portion and the Glu-Glu-Phe tag of the third domain. The point of crossover is impossible to determine as the coding sequences in the three copies of C3d are identical.

Subsequent attempts to isolate a stable virus containing three C3d domains by plaque cloning were unsuccessful. All viruses recovered contained only the single C3d domain determined by PCR analysis as described above.

### **Example 3. Design and Construction of a Fuzzy Gene encoding C3d monomer**

#### **(a) Synthetic gene design**

Homologous recombination occurs as a result of DNA strand exchange between regions of homology. In the present invention a series of synthetic C3d domains are constructed in such a way to reduce to a minimum the presence of homologous DNA when the sequences are concatenated, without altering the coding sequence of the C3d domain. The basis of the invention is to utilise the third base "wobble" phenomenon to introduce silent changes throughout the domain. The number of possible variants of this is very large, and not cannot be specified individually. Where third base "wobble" is introduced the variations shown in Table 1 are included. Certain third base "wobble" options are specifically avoided where a codon was found to be rare in mammalian, insect or bacterial genomes. Codons with variable third base positions are described hereinafter as "fuzzy" codons.

Table 1

Amino acid	Codon	Rare codons	fuzzy codon	reverse fuzzy codon
Ala	GCN	none	GCN	NGC
Arg	CGN or AGR	CGG <sup>2,3</sup> CGA <sup>1,2,3</sup>	CGY	RCG
Asn	AAY	none	AAY	RTT
Asp	GAY	none	GAY	RTC
Cys	TGY	none	TGY	RCA
Gln	CAR	none	CAR	YTG
Glu	GAR	none	GAR	YTC
Gly	GGN	none	GGN	NCC
His	CAY	CAT <sup>2</sup>	CAC	GTG
Ile	ATH	ATA <sup>3</sup>	ATY	RAT
Leu	CTN or TTR	CTA <sup>1,2,3</sup>	CTB	VAG
Lys	AAR	none	AAR	YTT
Phe	TTY	none	TTY	YAA
Pro	CCN	CCC <sup>3</sup> CCG <sup>1</sup> ,	CCW	SGG
Ser	TCN or AGY	TCG <sup>1</sup>	TCH	DGA
Thr	ACN	none	ACN	NGT
Tyr	TAY	none	TAY	RTA
Val	GTN	none	GTN	NAC

NB: The codons for Met (ATG) and Trp (TGG) are invariant.

**Key:**

1	Rare codon in mammalian genome
2	Rare codon in insect genome
3	Rare codon in bacterial genome
R	A or G
Y	C or T
S	C or G
W	A or T
H	A or C or T
B	C or G or T
V	A or C or G
D	A or G or T
N	A or C or G or T

Twelve oligonucleotides ranging from 76 to 106 bases in length were synthesised encoding the upper or lower strand of the C3d sequence. Oligonucleotide Fuz1 (SEQ. ID No 1) encoded the first 79 bases of the C3d sequence (forward strand) preceded by 21 bases including a *Bgl*III site (in frame with the *Bgl*III site in pBP68-01) and a *Nde*I site (in frame with the *Nde*I site in pDB1032 and pDB1033). Of the 26 C3d amino acids codons present in Fuz1, the first 20 are encoded by fuzzy codons (with the exception of the invariant methionine codon ATG). The carboxy terminal 14 residues of Fuz1 are invariant, with codons selected where possible to be GC rich to enhance annealing of these complementary sequences. This region represents the region of overlap with Fuz2 (Seq. ID No 2). Oligonucleotide Fuz2 encodes amino acids 23 to 54 of C3d (reverse strand) where the reverse codons for amino acids 23-26 at the 3' end are invariant and overlap Fuz1. Amino acids 27 to 49 are encoded by reverse fuzzy codons (with the exception of the invariant tryptophan reverse codon CCA). At the 5' end the terminal 14 residues of Fuz2 are invariant, with reverse codons selected where possible to be GC rich. This region represents the region of overlap with Fuz3.

Fuz3 through to Fuz11 (SEQ. ID No 3 to No 11) were designed along similar lines, with a central region of fuzzy codons and invariant, GC-rich ends overlapping by 13-17 bases with the flanking oligonucleotides.

Fuz12 (Seq. ID No 12) overlaps with Fuz11 at the 3' end by 14 bases and has the central region of fuzzy codons encoding C3d, but the 5' end of the oligonucleotide which represents the carboxy terminus of the gene contains a linker region (Gly-Gly-Gly-Gly-Ser (in fuzzy codons), a *Bam*HI site, a stop codon and an *Eag*I site. The *Bam*HI site allows for subsequent fusion to the amino-terminal *Bg*III site of another C3d domain for concatenation of multiple domains. The stop codon will be retained only in the carboxy-terminal C3d domain, and the *Eag*I site allows for subsequent cloning into the baculovirus vector pBacPak8.

#### **(b) Gene assembly**

The fuzzy C3d gene was built in stages involving cycles of annealing and amplification using the polymerase change reaction (PCR) methodology these amplified segments are then ligated together.

In the first stage the fuzzy oligonucleotides were annealed in pairs through their GC-rich invariant overlapping regions in the following combinations; Fuz1 + Fuz2, Fuz3 + Fuz4, Fuz5 + Fuz6, Fuz7 + Fuz8, Fuz9 + Fuz10, Fuz11 + Fuz12. To amplify the paired fuzzy oligonucleotides PCR primers were designed each strand at the overlapping invariant GC rich region at the 5' end of the odd numbered oligonucleotides and to the 3' end of the even-numbered oligonucleotides. These PCR primers incorporated base changes that created novel restriction sites at each end of the overlapping pairs of fuzzy oligonucleotides. This property allowed trimming of the amplified DNA sequences by specific endonucleases to give cohesive ends that anneal the amplified fuzzy oligonucleotides in their correct orientation. An alternative PCR primer to Fuz12 termed Fuz25 (SEQ. ID No.25) was identical to Fuz12 except at its 5' end an additional codon was added prior to the stop codon to incorporate a C-terminal cysteine residue. This C-terminal cysteine in the expressed protein could be used subsequently to couple antigen to the C3d<sub>n</sub>



The PCR primers are listed in the Table 2 below showing the fuzzy oligonucleotide pairs they are designed to amplify and their unique restriction site:

**Table 2 PCR primers designed to amplify fuzzy oligonucleotide overlapping pairs**

Fuzzy oligonucleotide overlapping pairs	PCR primer	Strand	Novel restriction site
Fuz1 + Fuz2	Fuz23 (SEQ ID No. 23)	forward	None
	Fuz20 (SEQ ID No. 20)	reverse	<i>PvuII</i>
Fuz3 + Fuz4	Fuz19 (SEQ ID No. 19)	forward	<i>PvuII</i>
	Fuz14 (SEQ ID No. 14)	reverse	<i>XhoI</i>
Fuz5 + Fuz6	Fuz13 (SEQ ID No. 13)	forward	<i>XhoI</i>
	Fuz16 (SEQ ID No. 16)	reverse	<i>XmaI</i>
Fuz7 + Fuz8	Fuz15 (SEQ ID No. 15)	forward	<i>XmaI</i>
	Fuz18 (SEQ ID No. 18)	reverse	<i>BclI</i>
Fuz9 + Fuz10	Fuz17 (SEQ ID No. 17)	forward	<i>BclI</i>
	Fuz22 (SEQ ID No. 22)	reverse	<i>HindIII</i>
Fuz11 + Fuz12	Fuz21 (SEQ ID No. 21)	forward	<i>HindIII</i>
	Fuz24 (SEQ ID No. 24)	reverse	None
	Fuz25 (SEQ ID No. 25)	reverse	None

The PCR reactions were all carried out under identical conditions for each reaction containing a single pair of overlapping fuzzy oligonucleotides. The PCR reaction was carried out in a total reaction volume of 0.6ml containing fuzzy oligonucleotides at a final concentration of 1nM and the PCR oligonucleotides at 2µM in the combinations as described in Table 2 above, to this was added 48µl 2.5mM dNTPs, 60µl x10 Taq polymerase buffer (Promega), 48µl 25mM MgCl<sub>2</sub>, and 6µl Taq polymerase

(30 units) (Promega), sterile deionised water was added to give a final volume of 0.6ml. The temperature cycling was identical for all reactions: 94°C for 5min followed by 35 cycles of 50°C/2min; 72°C/3 minutes; 94°C/1 minutes; this was followed by an incubation at 72°C for 7 minutes.

The PCR reaction products were separated on a 1.3% (w/v) agarose gel and the amplified product at the correct size was excised from the gel and purified using either MERmaid Kit or MERmaid Spin Kit into 60µl of sterile deionised water.

The purified products from the PCR reaction were restriction endonuclease digested with the appropriate enzyme see Table 2 above to provide cohesive ends for ligation. Post restriction enzyme digest the DNA was buffer exchanged into 30µl sterile deionised water by purifying the DNA from solution using either MERmaid Kit or MERmaid spin Kit.

These fragments were either ligated either pairwise or in in trimers through their cohesive ends under standard conditions, e.g. sections Fuz1-2+3-4, 5-6+7-8, 9-10+11-12 or Fuz 1-2+3-4+5-6 or Fuz 7-8+9-10+11-12, as described in General Methods Section. Post ligation the ligated fragments were buffer exchanged using a Gene-Spin kit.

These ligated fragments were then digested with the appropriate restriction endonucleases for ligation into the vector (see Example 4 ) and then buffer exchanged from solution using a Gene-Spin kit. Alternatively the ligated fragments were further amplified under the same PCR conditions using a reaction mix containing 2µM of the appropriate PCR primers, 15µl of ligated DNA fragments, 4µl 2.5mM dNTPs, 5µl x10 Taq polymerase buffer (Promega), 4µl 25mM MgCl<sub>2</sub>, deionised water to 48µl and 2µl Taq polymerase (10 units) (Promega). The amplified product was excised from the gel and purified. The purified fragments were then digested with the appropriate restriction nuclease to allow ligation into the vector as detailed in Example 4 below.

A fuzzy C3d gene is directly assembled into pBP66-01 (see below for construction) or pBakPak8 vector following endonuclease digestion of pBP66-01 or pBakPak8 with *Bgl*III and *Eag*I and purification of the vector band after separation on a 0.7% agarose gel. The products of the PCR-amplified fuzzy oligonucleotide pairs products are digested to provide the cohesive ends between adjacent fuzzy fragments.

Additionally the fragments containing the 5' and 3' ends of the fuzzy gene were digested with *Bgl*III and *Eag*I respectively. The six restriction enzyme digested PCR products are purified by agarose gel electrophoresis and purified, then are ligated into the *Bgl*III/*Eag*I digested pBP66-01 or pBakPak8 fragments under standard conditions. The ligated vectors is then transformed into *E. coli* XL-1 blue competent cells. These vectors are termed are termed pBP66-10 to 19 (pBP66-01-derived) or pBP66-20 to 29 (pBakPak8-derived).

#### **Example 4. Construction and Expression of Fuzzy Genes encoding (C3d)<sub>3</sub> using variants of the C3d sequence**

##### **(a) Construction of the pBP68-30 series: baculovirus vectors for (C3d)<sub>3</sub> which are resistant to homologous recombination**

pBP68-30 through to pBP68-39 contain three different variants of the C3d sequence that have been demonstrated by repeated passage in insect cells to be resistant to homologous recombination, see General Methods Section (xi), by virtue of sequence variation introduced at the third base "wobble" position in the first and second C3d domains. The pBP68-30 series of plasmids were constructed in two steps. In the first step, pBP68-01 was digested with the restriction enzyme *Sac*I which cleaves once within each C3d domain. The 6725 base pairs vector fragment was purified and self-ligated to form pBP66-01. pBP66-01 contains a single C3d domain containing a signal peptide at the amino terminus and the Glu-Glu-Phe tag at the carboxy terminus. pBP66-01 was transformed into XL-1 blue *E. coli* and DNA extracted from the resulting colonies analysed by restriction digest.

In the second step pBP66-01 is digested with the restriction enzyme *Bgl*III. Fuzzy C3d domains or fragments were assembled as described in Example 3(b). PCR fragments or full-length products or plasmid vectors into which such products have been subcloned were digested with *Bam*HI and *Bgl*III and DNA fragments of 936 base pairs encoding single fuzzy C3d domains were purified and ligated with this fragment. Smaller fragments of fuzzy C3d may also be generated in Example 3(b) and these are

digested with appropriate restriction enzymes to generate compatible cohesive ends to reconstruct a full length fuzzy C3d domain.

The sequence of individual variants of the fuzzy C3d domains may be determined prior to this ligation following subcloning into a holding vector such as pBC00-02 (see below) or the ligation may be carried out using uncharacterised and potentially heterogeneous mixtures of PCR products generated in Example 3 (b).

The resulting plasmids are designated p BC66-10 to 19 where a single fuzzy C3d domain is cloned into pBC00-02 (for sequencing or bacterial expression), pBP67-20 to pBP67-29 where the baculovirus expression vector contains one fuzzy C3d domain and one invariant C3d domain, or pBP68-30 to pBP68-39 where the baculovirus expression vector contains two different fuzzy C3d domains and one invariant C3d domain.

As an alternative strategy, the plasmid pBP66-01 is subjected to site directed mutagenesis to introduce unique restriction enzyme sites corresponding to the restriction enzyme sites engineered into the termini of the PCR products representing sub-domains of fuzzy C3d described in Table 2 such that the PCR primer pair Fuz13 and Fuz14 (SEQ ID Nos.13/14) are used to generate a novel *Xho*I site at position 1713 in pBC66-01, numbering according to SEQ ID No.32; the PCR primer pair Fuz15/Fuz16 (SEQ ID Nos.15/16) are used to generate a novel *Xma*I site at position 1866 in pBC66-01; the PCR primer pair Fuz17/Fuz18 (SEQ ID Nos.17/18) are used to generate a novel *Bcl*II site at position 2060 in pBC66-01; the PCR primer pair Fuz21/Fuz22 (SEQ ID Nos.21/22) are used to generate a novel *Hind*III site at position 2222 in pBC66-01. These restriction sites and a unique *Pvu*II site present in the invariant sequence at position 1553 are utilised to excise specific fragments of the invariant C3d sequence. These are replaced with corresponding fuzzy C3d fragments generated in Example 3 (b) having compatible cohesive ends, identical amino acid coding sequence, but fuzzy DNA sequence at the third base "wobble" position as described in Example 3 (a).

The resulting plasmids where the restriction sites are introduced into invariant C3d sequence are designated pBP66-02 (*Xho*I site), pBP66-03 (*Xma*I site), pBP66-04 (*Bcl*II site), pBP66-05 (*Hind*III site).

**(b) Expression of (C3d)3 using fuzzy gene variants of the C3d sequence in Baculovirus/Sf9 system**

Recombinant baculoviruses are generated from the plasmids constructed as described in Section (a), this example, and used to express the encoded polypeptide according to the methods described in General Methodology Sections (viii) to (x).

**(c) Purification and Characterisation of the (C3d)3 Expressed from the fuzzy variants**

The (C3d)3 protein is purified as described in Section (xiv) of General Methods. The purified protein is characterised biologically by the methods described in Section (xvii) and physically characterised as described in Sections (xv) and (xvi) (b-c) and its exact mass determined by mass spectrometry. N-terminal sequence is also determined.

**(b) Construction of the pBC66-10, pBC67-10, pBC68-10; *E.coli* vectors for (C3d)3 which are resistant to homologous recombination**

pBroc413 is digested with the restriction endonucleases *NdeI* and *PstI* and the vector fragment isolated from a 0.9% (w/v) agarose gel. To create a new multi-cloning sites suitable for exchange of C3d variants between the pBakPak8 vector and a bacterial expression vector a new polylinker site described in SEQ ID no. 38 and 39 is ligated into the vector fragment. This new vector is called pBC00-02.

The plasmids designated pBP66-10 to 19 encode one fuzzy C3d domain. The series pBP67-20 to 29 encode one fuzzy C3d variant and the native C3d sequence and pBP68-30 to 39 contain two fuzzy C3d variant and a native the C3d sequence. These plasmids are digested with the restriction endonucleases *BglII* and *EagI* and the C3d encoding fragments purified from a 1% (w/v) agarose gel. PBC00-02 is similarly cut with *BglII* and *EagI* and the larger fragment (vector fragment) purified from a 0.9% (w/v) agarose gel.

The vector fragments and the C3d encoding fragments are ligated and transformed into *E. coli* XL-1 blue under standard condition and the clones isolated and screened by restriction mapping. The new plasmids are designated: pBC67-10 to 19 encoding one fuzzy C3d domain and pBC67-20 to 29 encoding one fuzzy C3d variant

and the native C3d sequence and pBC68-30 to 39 containing two fuzzy C3d variant and a native the C3d sequence

**Example 5. Construction and expression of a cysteine-tailed C3d monomer or (C3d)<sub>3</sub>**

**(a) Construction of pBP66-06 and pBP68-40 to pBP68-49**

The C-terminal cysteine is introduced by site direct mutagenesis of the plasmid pBP66-01 to form pBP66-06, and the pBP68-40 to pBP68-49 series of plasmids is constructed from the series pBP68-30 to pBP68-39. These plasmids, or a selected plasmid with a chosen variant of fuzzy C3d, are subjected to site directed mutagenesis with oligonucleotides with the following sequence:  
CAGTGGATCTTGCTAGAGTTCTGCAGGATC (Seq ID 33) and GATCCTGCAG  
AACTCTAGCAAGATCCACTG (Seq ID 34). Site directed mutagenesis is carried out using a "QuickChange" kit obtained from Stratagene (Cambridge UK.) according to the manufacturer's protocols. The resulting plasmids, pBP66-06 and pBP68-40 to pBP68-49 are transformed into competent *E. coli* XL1-blue purchased from Stratagene. Ampicillin resistant transformants are selected on LB-agar plates containing 50µg/ml ampicillin. Plasmid DNA extracted from the resulting colonies is identified initially by restriction enzyme digest and confirmed by DNA sequencing.

**(b) Expression of cysteine-tailed C3d and (C3d)<sub>3</sub> sequence in Baculovirus/Sf9 system**

Recombinant baculoviruses are generated from the plasmids constructed as described in Section (a), this example, and used to express the encoded polypeptide according to the methods described in "General Methodology used in examples" Sections (viii) to (x).

**(c) Purification and Characterisation of the cysteine-tailed C3d and (C3d)<sub>3</sub> Expressed from the fuzzy variants in Sf9/baculovirus system**

The (C3d)<sub>n</sub>-cys tailed protein is purified as described in Section (xiv) of General Methods, characterised biologically by the methods described in Section (xvii) and physically characterised as described in (xv) and (xvi) (b-c).

**(d) Conjugation of C3d-cys or (C3d)<sub>3</sub>-cys with antigen**

Purified C3d<sub>n</sub>-cys is treated with Tris (2-carboxyethyl) phosphine.HCl (TCEP) to remove any blocking moiety on the C-terminal cysteine. Thus, C3d<sub>n</sub> (10μM; 1 ml) is mixed with TCEP (5mM in 50mM HEPES pH 4.5; 0.008 ml) and incubated at 20 to 25°C for about 18h to give solution A. Antigen is prepared typically by chemical attachment of a suitable linking group to the antigen followed by conjugation to the free cysteine on the (C3d)<sub>3</sub> molecule. Antigen (20μM in 0.1M Trien pH 8.0; 1.0ml) is mixed with 2-iminothiolane (10mM in 0.1M Trien pH 8.0; 0.01ml) and incubated at 20 to 25°C for 1h. DTNB (100mM in 0.1M Trien pH 8.0; 0.01ml) is added and the mixture left for a further 1h. The mixture is then buffer exchanged into 0.1M Trien pH 8.0 (2.0ml) using Sephadex G25 (PD10; Pharmacia) to give solution B. Solution B (1.0ml) is mixed with solution A (1.0ml) and incubated at 20 to 25°C for 18 h optionally with concentration by ultrafiltration to give solution C. Solution C is optionally purified to remove unreacted materials, for example by size exclusion chromatography, and then formulated into final product. This formulation may involve buffer-exchange into a physiologically acceptable buffer, for example phosphate buffered saline, followed by sterile filtration, aliquoting and freezing or it may involve buffer-exchange into a suitable buffer for lyophilisation.

**Example 6. Construction of a vector for expression of an unspecified gene product fused to (C3d)<sub>3</sub>.**

In this example any of the above plasmids used for expression of C3d monomer or oligomers is modified by the addition of sequences specifying a range of commonly utilised restriction enzyme sites which are not found elsewhere in the plasmid. This is known as the polylinker, and is intended to provide convenient sites for insertion of an

unspecified DNA fragment encoding a polypeptide which results in an in-frame fusion between the mature C3d protein or C3d oligomer, either at the amino terminus or the carboxy terminus. The sequence comprising the polylinker is provided in three formats where the restriction sites are shifted by one base to facilitate in frame fusions of the unspecified DNA fragments.

#### **Example 7. Expression and purification of C3d oligomers as Intein fusion proteins**

##### **(a) Construction of pBP66-07 and pBP68-50 to pBP68-59.**

In this example, a form of C3d or C3d oligomers is expressed with a carboxy terminal reactive thiolester allowing direct covalent coupling to the antigen of choice. It should be noted the natural C3d sequence normally contains a thiolester that is buried in native C3 and is the site of attachment to antigen in C3b and its fragments. In the plasmid pSG.C3d<sub>1</sub>.YL and its derivatives, the cysteine residue that is the biosynthetic precursor of the natural thiolester is mutated to prevent interference with disulphide bond formation in recombinant C3d proteins (Dempsey *et al*, Science 271, 348-350, 1996). In the present construct the thiolester is effectively moved to the C-terminus of the C3d domain.

The carboxy terminal of C3d in the vector pBP66-01 or any of the pBP68-30 to pBP68-39 series is modified by site directed mutagenesis to introduce novel restriction sites *SapI* and *PstI* using oligonucleotides #50391 (Seq ID No 35) (CCAGCAGTGGCTCTTCCTGCTTCTG CAGGATC) and #50392 (Seq ID No 36) (GATCCTGCAGAAGCAGGAAGAGCCACT GCTGG). Site directed mutagenesis is carried out using a "QuickChange" kit obtained from Stratagene according to the manufacturer's protocols. The resulting plasmids, pBP66-07 and pBP68-50 to pBP68-59 are transformed into competent *E. coli* XL1-blue purchased from Stratagene. Ampicillin resistant transformants are selected on LB-agar plates containing 50µg/ml ampicillin.



Plasmid DNA extracted from the resulting colonies is identified initially by restriction enzyme digest and confirmed by DNA sequencing.

#### **b) Construction of pBP81-01 and pBP83-50 to pBP83-59**

pBP81-01 and pBP83-50 to pBP83-59 are plasmids in which the genes for intein and the chitin binding domain are cloned in frame downstream of the C3d-wild type or (C3d)3 in which one or more of the domains is fuzzy to prevent homologous recombination. The intein and chitin binding domain sequences are obtained from the commercially available plasmid pCYB1 (New England Biolabs) by digestion with the enzymes *SapI* and *PstI* and purification of the 1560 base pair fragment, this is termed fragment 1. pBP66-07 and pBP68-50 to pBP68-59 are digested with *SapI* and *PstI* and a fragment of 6718 base pairs is purified from pBP66-07 (Fragment 2) and a fragment of 8590 base pairs is purified from pBP68-50 to pBP68-59 (fragments 3a-3j).

Fragments 1 and 2 are ligated using T4 DNA ligase to give pBP81-01. Fragments 3a to 3j fragments are each ligated with fragment 1 using T4 DNA ligase to give pBP83-50 to pBP83-59. The ligated plasmids are transformed into competent *E. coli* XL1-blue purchased from Stratagene. Ampicillin resistant transformants are selected on LB-agar plates containing 50µg/ml ampicillin. Plasmid DNA extracted from the resulting colonies is analysed by restriction endonuclease digestion and confirmed by DNA sequencing.

#### **(c) Expression of C3d oligomers fused to intein and chitin binding protein**

Recombinant baculoviruses are generated from the plasmids constructed as described in Section b) (this example) and used to express the encoded polypeptide according to the methods described in "General Methodology used in examples" Sections (viii) to (x).

#### **(d) Purification and cleavage of C3d<sub>n</sub>-intein fusion proteins to generate carboxy terminal reactive thiolester**

The C3d<sub>n</sub>-intein-chitin binding domain fusion protein is purified from material expressed into the media by the Sf9 infected baculovirus cells. Prior to loading onto the chitin bead affinity column (New England Biolabs, Herts) the pH of the media is corrected to pH 8.0 by addition of 10M NaOH. The salt concentration of the media is measured by conductivity, usually about 0.08M and solid NaCl added to the media to give a final concentration of 0.5M NaCl.

The C3d<sub>n</sub>-intein-chitin binding domain fusion containing supernatant is loaded onto the chitin bead affinity matrix column and separation carried out according to the instructions in the 'IMPACT I' kit (New England Biolabs, Herts, UK). The cleavage on the column utilises a protein splicing mechanism known as an intein and this undergoes a self cleavage reaction between the C-terminal of the C3d<sub>n</sub> and the N-terminal of the intein in the presence of a reducing agent e.g. DTT. As a result of this reaction the eluted C3d<sub>n</sub> contains a reactive thiolester at its C-terminal. The resulting affinity purified protein should be at least 90% pure, if the purity is less than 90% prior to coupling to antigen it should be further purified using techniques described in General Methods Section (xiv).

**(e) Reaction with C3d(n)-thiolester with antigen.**

The activated thiolester produced by the cleavage at the C-terminal of C3d<sub>n</sub> by the intein mechanism (Section d above) is used to couple antigen to the molecule. The thiolester reacts with free nucleophiles on the surface of the antigen e.g. the ε-amino group of lysine or under some circumstances with hydroxyl groups in the side chains of amino-acids such as serine and tyrosine or in the sugar groups of glycosylated proteins. Preferably the antigen is present in molar excess over the thiolester and is preferably added to the purified C3d<sub>n</sub> after elution from the column and during processing to remove the DTT (which acts as a competing nucleophile) and to co-concentrate the proteins. The formation of the antigen-C3d is monitored by mass spectrometry and/or gel electrophoresis to detect all the species in the population. The complexes containing at least one C3d and one antigen unit are separated by gel filtration or by separation through a size exclusion membrane that allows separation of the multimers from the monomers.

### **Example 8. Construction of a fuzzy genes encoding species variants of (C3d)3**

All the above examples employed the murine C3d sequence. Using methodology described in Example 3, fuzzy C3d sequences are devised for any species including but not restricted to human, cat, rabbit, bovine, ovine, equine and goat to generate a series of variants containing either a single C3d domain, or two independent fuzzy variant domains of C3d and a single domain of invariant DNA sequence. Subsequent modifications described in all later Examples are carried out in an identical manner.

Where the sequence is known e.g. human (de Bruin and Fey (1985) PNAS (USA) 82:708-712) the Fuzzy oligonucleotides are generated directly; in cases where the sequence is unknown C3d hybridisation probes from either the human or mouse are used to identify and therefore clone and sequence C3d from the chosen species library.

Seq ID No1: DNA sequence of Fuz1

CACCCGAGCCATATGAGATCTACNCCWGCNGGNTCHGGNGARCARAAYATG  
ATYGGNATGACNCCWACNGTNATYGCNGTNCACCTACCTGGACCAGACCG

Seq ID No2: DNA sequence of Fuz2

GGCCAGCTGCTGGGTRTANCCYTTYTTRATVAGYTCVAGNGCYTCYTGRGCGY  
TTYTCRATNCCRAAYTTYTCCCAYTGYTCGGTCTGGTCCAGG

Seq ID No 3: DNA sequence of Fuz3

CCCAGCAGCTGGCCTTYAARCARCCWTCHTCHGCNTAYGCNGCNTTYAAYAA  
YCGYCCWCCWTCHACNTGGCTBACNGCCTACGTGGTCAAGG

Seq ID No 4: DNA sequence of Fuz4

CCGGCTTCTGCTTCTCCAGRATVAGCCAYTTNACNGCNCCRCVAGNACGTG  
DGARTCRATNGCRATVAGRTTNGCNGCVAGDGARAANACCTTGACCACGTAG  
GC

Seq ID No 5: DNA sequence of Fuz5

GGAGAAGCAGAAGCCGGAYGGNGTNTTYCARGARGAYGGNCCWGTNATYCA  
CCARGARATGATYGGNGGNTTYCGNAACGCCAAGGAGGC  
AGATG

Seq ID No 6: DNA sequence of Fuz6

GCTCCCAGGAAGGCTRTTNACYTGNCCYTCRCARATRTCRGNGCYTCYTG  
V  
AGNGCRATVAGNACRAANGCNGTVAGDGANACATCTGCCTCCTTGGCG

Seq ID No 7: DNA sequence of Fuz7

GCCTTCCTGGGAGCATYAAYAARGCNGGNGARTAYATYGARGCNTCHTAYAT  
GAAYCTBCARCGYCCWTAYACNGTNGCNATYGCNGGGTATGCCCTGGCC

Seq ID No 8: DNA sequence of Fuz8

CTGGTCAGGCTCCTCCCARCGRTTRCGRTCYTNGCNGTRTTVAGRAAYTTNC  
CNAGRТАWGGYTCYTCVAGYTTTTCATVAGGGCCAGGGCATACCC

Seq ID No9: DNA sequence of Fuz9

GAGGAGCCTGACCAGCARCTBTAYAAYGTNGARGCNACNTCHTAYGCNCTBC  
TBGCNCTBCTBCTBCTBAARGAYTTYGAYTCHGTGCCCCCTGTAGTGC

Seq ID No10: DNA sequence of Fuz10

GGGCAAGGCTTGGAANACCATRAANGTNGCYTGNGTDGANCCRTANCCNC  
CNCRTARTARCGYTGTCRTTVAGCCANCGCACTACAGGGGGC

Seq ID No 11: DNA sequence of Fuz11

CCAAGCCTTGGCCARTAYCARACNGAYGTNCCWGAYCACAARGAYCTNAA  
YATGGAYGTNTCCTTCCACCTCCCC

Seq ID No 12: DNA sequence of Fuz12.

CCCAGAGCCGGCCGGTTATCAGGATCCDGANCCNCCNCCNCCDGANCCNCCN  
CCNCCDGANCCDGAAGAGGGGAGGTGGAAGG

Seq ID No 13: DNA sequence of Fuz13

GGC TGA TTC TCG AGA AGC AGA AGC

Seq ID No 14: DNA sequence of Fuz14

GCT TCT GCT TCT CGA GAA TCA GCC

Seq ID No 15: DNA sequence of Fuz15

GCC TTC CCG GGA GCA TCA ACA AGG C

Seq ID No 16: DNA sequence of Fuz16

GCC TTG TTG ATG CTC CCG GGA AGG C

Seq ID No 17: DNA sequence of Fuz17

GGA GCC TGA TCA GCA GCT CTA CAA CG

Seq ID No 18: DNA sequence of Fuz18

CGT TGT AGA GCT GCT GAT CAG GCT CC

Seq ID No 19: DNA sequence of Fuz19

GGGTACACCCAGCAGCTGGCC

Seq ID No 20: DNA sequence of Fuz20

GGCCAGCTGCTGGGTGTACCC

Seq ID No 21: DNA sequence of Fuz21  
GGTGTCCAAGCTTTGGCCC

Seq ID No 22: DNA sequence of Fuz22  
GGGCCAAAGCTTGGAACACC

Seq ID No 23: DNA sequence of Fuz23  
CACCCGAGCCATATGAG

SEQ ID No 24: DNA sequence of Fuz24  
CCCAGAGCCGCGCGTTATCAGGATCC

SEQ ID No 25 DNA sequence of Fuz25  
CCC AGA GCC GGC CGG TTA GCA GGA TCC

#### SEQ ID No26

C3d1 amino acid sequence expressed in *E.coli*

1	Met Ala Ser Gly Ser Thr Pro Ala Gly Ser
11	Gly Glu Gln Asn Met Ile Gly Met Thr Pro
21	Thr Val Ile Ala Val His Tyr Leu Asp Gln
31	Thr Glu Gln Trp Glu Lys Phe Gly Ile Glu
41	Lys Arg Gln Glu Ala Leu Glu Leu Ile Lys
51	Lys Gly Tyr Thr Gln Gln Leu Ala Phe Lys
61	Gln Pro Ser Ser Ala Tyr Ala Ala Phe Asn
71	Asn Arg Pro Pro Ser Thr Trp Leu Thr Ala
81	Tyr Val Val Lys Val Phe Ser Leu Ala Ala
91	Gln Leu Ile Ala Ile Asp Ser His Val Leu
101	Cys Gly Ala Val Lys Trp Leu Ile Leu Glu
111	Lys Gln Lys Pro Asp Gly Val Phe Gln Glu
121	Asp Gly Pro Val Ile His Gln Glu Met Ile
131	Gly Gly Phe Arg Asn Ala Lys Glu Ala Asp
141	Val Ser Leu Thr Ala Phe Val Leu Ile Ala
151	Leu Gln Glu Ala Arg Asp Ile Cys Glu Gly

51

161 Gln Val Asn Ser Leu Pro Gly Ser Ile Asn  
171 Lys Ala Gly Glu Tyr Ile Glu Ala Ser Tyr  
181 Met Asn Leu Gln Arg Pro Tyr Thr Val Ala  
191 Ile Ala Gly Tyr Ala Leu Ala Leu Met Asn  
201 Lys Leu Glu Glu Pro Tyr Leu Gly Lys Phe  
211 Leu Asn Thr Ala Lys Asp Arg Asn Arg Trp  
221 Glu Glu Pro Asp Gln Gln Leu Tyr Asn Val  
231 Glu Ala Thr Ser Tyr Ala Leu Leu Ala Leu  
241 Leu Leu Leu Lys Asp Phe Asp Ser Val Pro  
251 Pro Val Val Arg Trp Leu Asn Glu Gln Arg  
261 Tyr Tyr Gly Gly Gly Tyr Gly Ser Thr Gln  
271 Ala Thr Phe Met Val Phe Gln Ala Leu Ala  
281 Gln Tyr Gln Thr Asp Val Pro Asp His Asp  
291 Leu Asn Met Asp Val Ser Phe His Leu Pro  
301 Ser Ser Gly Ser Glu Glu Phe

SEQ ID No 27

(C3d)3 amino acid sequence expressed in *E.coli*

1 Met Ala Ser Gly Ser Thr Pro Ala Gly Ser  
11 Gly Glu Gln Asn Met Ile Gly Met Thr Pro  
21 Thr Val Ile Ala Val His Tyr Leu Asp Gln  
31 Thr Glu Gln Trp Glu Lys Phe Gly Ile Glu  
41 Lys Arg Gln Glu Ala Leu Glu Leu Ile Lys  
52 Lys Gly Tyr Thr Gln Gln Leu Ala Phe Lys  
62 Gln Pro Ser Ser Ala Tyr Ala Ala Phe Asn  
72 Asn Arg Pro Pro Ser Thr Trp Leu Thr Ala  
82 Tyr Val Val Lys Val Phe Ser Leu Ala Ala  
91 Gln Leu Ile Ala Ile Asp Ser His Val Leu  
102 Cys Gly Ala Val Lys Trp Leu Ile Leu Glu  
112 Lys Gln Lys Pro Asp Gly Val Phe Gln Glu  
122 Asp Gly Pro Val Ile His Gln Glu Met Ile  
132 Gly Gly Phe Arg Asn Ala Lys Glu Ala Asp  
141 Val Ser Leu Thr Ala Phe Val Leu Ile Ala  
152 Leu Gln Glu Ala Arg Asp Ile Cys Glu Gly  
162 Gln Val Asn Ser Leu Pro Gly Ser Ile Asn

51

172 Lys Ala Gly Glu Tyr Ile Glu Ala Ser Tyr  
182 Met Asn Leu Gln Arg Pro Tyr Thr Val Ala  
191 Ile Ala Gly Tyr Ala Leu Ala Leu Met Asn  
202 Lys Leu Glu Glu Pro Tyr Leu Gly Lys Phe  
212 Leu Asn Thr Ala Lys Asp Arg Asn Arg Trp  
222 Glu Glu Pro Asp Gln Gln Leu Tyr Asn Val  
232 Glu Ala Thr Ser Tyr Ala Leu Leu Ala Leu  
241 Leu Leu Leu Lys Asp Phe Asp Ser Val Pro  
252 Pro Val Val Arg Trp Leu Asn Glu Gln Arg  
262 Tyr Tyr Gly Gly Gly Tyr Gly Ser Thr Gln  
272 Ala Thr Phe Met Val Phe Gln Ala Leu Ala  
282 Gln Tyr Gln Thr Asp Val Pro Asp His Asp  
292 Leu Asn Met Asp Val Ser Phe His Leu Pro  
301 Ser Ser Gly Ser Gly Gly Gly Gly Ser Gly  
311 Gly Gly Gly Ser Gly Ser Thr Pro Ala Gly  
321 Ser Gly Glu Gln Asn Met Ile Gly Met Thr  
331 Pro Thr Val Ile Ala Val His Tyr Leu Asp  
341 Gln Thr Glu Gln Trp Glu Lys Phe Gly Ile  
351 Glu Lys Arg Gln Glu Ala Leu Glu Leu Ile  
361 Lys Lys Gly Tyr Thr Gln Gln Leu Ala Phe  
371 Lys Gln Pro Ser Ser Ala Tyr Ala Ala Phe  
381 Asn Asn Arg Pro Pro Ser Thr Trp Leu Thr  
391 Ala Tyr Val Val Lys Val Phe Ser Leu Ala  
401 Ala Gln Leu Ile Ala Ile Asp Ser His Val  
411 Leu Cys Gly Ala Val Lys Trp Leu Ile Leu  
421 Glu Lys Gln Lys Pro Asp Gly Val Phe Gln  
431 Glu Asp Gly Pro Val Ile His Gln Glu Met  
441 Ile Gly Gly Phe Arg Asn Ala Lys Glu Ala  
451 Asp Val Ser Leu Thr Ala Phe Val Leu Ile  
461 Ala Leu Gln Glu Ala Arg Asp Ile Cys Glu  
471 Gly Gln Val Asn Ser Leu Pro Gly Ser Ile  
481 Asn Lys Ala Gly Glu Tyr Ile Glu Ala Ser  
491 Tyr Met Asn Leu Gln Arg Pro Tyr Thr Val  
501 Ala Ile Ala Gly Tyr Ala Leu Ala Leu Met  
511 Asn Lys Leu Glu Glu Pro Tyr Leu Gly Lys  
521 Phe Leu Asn Thr Ala Lys Asp Arg Asn Arg



531 Trp Glu Glu Pro Asp Gln Gln Leu Tyr Asn  
541 Val Glu Ala Thr Ser Tyr Ala Leu Leu Ala  
551 Leu Leu Leu Leu Lys Asp Phe Asp Ser Val  
561 Pro Pro Val Val Arg Trp Leu Asn Glu Gln  
571 Arg Tyr Tyr Gly Gly Gly Tyr Gly Ser Thr  
581 Gln Ala Thr Phe Met Val Phe Gln Ala Leu  
591 Ala Gln Tyr Gln Thr Asp Val Pro Asp His  
601 Asp Leu Asn Met Asp Val Ser Phe His Leu  
611 Pro Ser Ser Gly Ser Gly Gly Gly Gly Ser  
621 Gly Gly Gly Gly Ser Gly Ser Thr Pro Ala  
631 Gly Ser Gly Glu Gln Asn Met Ile Gly Met  
641 Thr Pro Thr Val Ile Ala Val His Tyr Leu  
651 Asp Gln Thr Glu Gln Trp Glu Lys Phe Gly  
661 Ile Glu Lys Arg Gln Glu Ala Leu Glu Leu  
671 Ile Lys Lys Gly Tyr Thr Gln Gln Leu Ala  
681 Phe Lys Gln Pro Ser Ser Ala Tyr Ala Ala  
691 Phe Asn Asn Arg Pro Pro Ser Thr Trp Leu  
701 Thr Ala Tyr Val Val Lys Val Phe Ser Leu  
711 Ala Ala Gln Leu Ile Ala Ile Asp Ser His  
721 Val Leu Cys Gly Ala Val Lys Trp Leu Ile  
731 Leu Glu Lys Gln Lys Pro Asp Gly Val Phe  
741 Gln Glu Asp Gly Pro Val Ile His Gln Glu  
751 Met Ile Gly Gly Phe Arg Asn Ala Lys Glu  
761 Ala Asp Val Ser Leu Thr Ala Phe Val Leu  
771 Ile Ala Leu Gln Glu Ala Arg Asp Ile Cys  
781 Glu Gly Gln Val Asn Ser Leu Pro Gly Ser  
791 Ile Asn Lys Ala Gly Glu Tyr Ile Glu Ala  
801 Ser Tyr Met Asn Leu Gln Arg Pro Tyr Thr  
811 Val Ala Ile Ala Gly Tyr Ala Leu Ala Leu  
821 Met Asn Lys Leu Glu Glu Pro Tyr Leu Gly  
831 Lys Phe Leu Asn Thr Ala Lys Asp Arg Asn  
841 Arg Trp Glu Glu Pro Asp Gln Gln Leu Tyr  
851 Asn Val Glu Ala Thr Ser Tyr Ala Leu Leu  
861 Ala Leu Leu Leu Leu Lys Asp Phe Asp Ser  
871 Val Pro Pro Val Val Arg Trp Leu Asn Glu  
881 Gln Arg Tyr Tyr Gly Gly Gly Tyr Gly Ser

891 Thr Gln Ala Thr Phe Met Val Phe Gln Ala  
901 Leu Ala Gln Tyr Gln Thr Asp Val Pro Asp  
911 His Asp Leu Asn Met Asp Val Ser Phe His  
921 Leu Pro Ser Ser Gly Ser Glu Glu Phe

SEQ. ID No 28  
TATGGCTAGCG

SEQ. ID No 29  
ACCGATCGCCTAG

Seq ID No 30: DNA sequence of PCR forward primer #39171

GAATTCCTAGCTTGCTTG

Seq ID No 31: DNA sequence of PCR reverse primer #39172

TCTAGAGTCGACCAGAC

Seq ID No 32 DNA sequence of pBP66-01

1	AACGGCTCCG CCCACTATTA ATGAAATTAA AAATTCCAAT TTTAAAAAAC	50
51	GCAGCAAGAG AAACATTTGT ATGAAAGAAT GCGTAGAAGG AAAGAAAAAT	100
101	GTCGTCGACA TGCTGAACAA CAAGATTAAT ATGCCTCCGT GTATAAAAAA	150
151	AATATTGAAC GATTTGAAAG AAAACAATGT ACCGCGCGGC GGTATGTACA	200
201	GGAAGAGGTT TATACTAAAC TGTTACATTG CAAACGTGGT TTCGTGTGCC	250
251	AAGTGTGAAA ACCGATGTTT AATCAAGGCT CTGACGCATT TCTACAACCA	300
301	CGACTCCAAG TGTGTGGGTG AAGTCATGCA TCTTTTAATC AAATCCCAAG	350
351	ATGTGTATAA ACCACCAAAC TGCCAAAAAA TGAAAACGTG CGACAAGCTC	400
401	TGTCCGTTTG CTGGCAACTG CAAGGGTCTC AATCCTATTT GTAATTATTG	450
451	AATAATAAAA CAATTATAAA TGCTAAATTT GTTTTTTATT AACGATACAA	500
501	ACCAAACGCA ACAAGAACAT TTGTAGTATT ATCTATAATT GAAAACGCGT	550

55

551	AGTTATAATC GCTGAGGTAA TATTTAAAAT CATTTTCAAA TGATTCACAG	600
601	TTAATTTGCG ACAATATAAT TTTATTTTCA CATAAACTAG ACGCCTTGTC	650
651	GTCTTCTTCT TCGTATTCCCT TCTCTTTTTT ATTCTTCTCC TCATAAAAAT	700
701	TAACATAGTT ATTATCGTAT CCATATATGT ATCTATCGTA TAGAGTAAAT	750
751	TTTTTGTTGT CATAAATATA TATGTCTTTT TTAATGGGGT GTATAGTACC	800
801	GCTGCGCATA GTTTTTCTGT AATTTACAAC AGTGCTATTT TCTGGTAGTT	850
851	CTTCGGAGTG TGTTGCTTTA ATTATTAAAT TTATATAATC AATGAATTTG	900
901	GGATCGTCGG TTTTGTACAA TATGTTGCCG GCATAGTACG CAGCTTCTTC	950
951	TAGTTCAATT ACACCATTTT TTAGCAGCAC CGGATTAACA TAACCTTTCCA	1000
1001	AAATGTTGTA CGAACCGTTA AACAAAAACA GTTCACCTCC CTTTTCTATA	1050
1051	CTATTGTCTG CGAGCAGTTG TTTGTTGTTA AAAATAACAG CCATTGTAAT	1100
1101	GAGACGCACA AACTAATATC ACAAACTGGA AATGTCTATC AATATATAGT	1150
1151	TGCTGATATC ATGGAGATAA TTAAAAATGAT AACCATCTCG CAAATAAATA	1200
1201	AGTATTTTAC TGTTTTTCGTA ACAGTTTGT AATAAAAAAA CCTATAAATA	1250
1251	CGGATCCCG GGAATTCCTAG CTTGCTTGTT CTTTTTGCAG AAGCTCAGAA	1300
1301	TAAACGCTC AACTTTGGCCA TGGCCCTCTG GATGCGCCTC CTGCCCCCTGC	1350
1351	TGGCCCTGC TGGCCCTCTGG GCGCCCGCGC CCACCCGAGC CGGATCCAGA	1400
1401	TCTACCCCC GCAGGCTCTGG GGAACAGAAC ATGATTGGCA TGACACCAAC	1450
1451	AGTCATTGC GGTACACTACC TGGACCAGAC CGAACAGTGG GAGAAGTTCC	1500
1501	GCATAGAGA AGAGGCAAGAG GCCCTGGAGC TCATCAAGAA AGGGTACACC	1550
1551	CAGCAGCTG GCCTTCAAACA GCCCAGCTCT GCCTATGCTG CCTTCAACAA	1600
1601	CCGGCCCCC CAGCACCTGGC TGACAGCCTA CGTGGTCAAG GTCTTCTCTC	1650
1651	TAGCTGCCA ACCTCATCGCC ATCGACTCTC ACGTCCTGTG TGGGGCTGTT	1700
1701	AAATGGTTG ATTCTGGAGAA ACAGAAGCCG GATGGTGTCT TTCAGGAGGA	1750
1751	TGGGCCCCG GATTACCAAG AAATGATTGG TGGCTTCCGG AACGCCAAGG	1800
1801	AGGCAGATGT GTCCTCACA GCCTTCGTCC TCATCGCACT GCAGGAAGCC	1850
1851	AGGGACATCT GTGAGGGGCA GGTCAATAGC CTTCTGGGA GCATCAACAA	1900
1901	GGCAGGGGAG TATATTGAAG CCAGTTACAT GAACCTGCAG AGACCATACA	1950
1951	CAGTGGCCAT TGCTGGGTAT GCCCTGGCCC TGATGAACAA ACTGGAGGAA	2000
2001	CCTTACCTCG GCAAGTTTCT GAACACAGCC AAAGATCGGA ACCGCTGGGA	2050
2051	GGAGCCTGAC CAGCAGCTCT ACAACGTAGA GGCCACATCC TACGCCCTCC	2100
2101	TGGCCCTGCT GCTGCTGAAA GACTTTGACT CTGTGCCCCC TGTTAGTGCGC	2150
2151	TGGCTCAATG AGCAAAGATA CTACGGAGGC GGCTATGGCT CCACCCAGGC	2200
2201	TACCTTCATG GTATTCCAAG CCTTGGCCCA ATATCAAACA GATGTCCCTG	2250
2251	ACCATAAGGA CTTGAACATG GATGTGTCCT TCCACCTCCC CAGCAGTGGA	2300
2301	TCTGGTGGAG GTGGAAGTGG TGGAGGTGGA GAAGAGTTCT GAGGATCTTA	2350
2351	TTAAAGCAGA ACTTGTTTAT TGCAGCTTAT AATGGTTACA AATAAAGCAA	2400
2401	TAGCATCACA AATTTACAA ATAAAGCATT TTTTCACTG CATTCTAGTT	2450

55

56

2451	GTGGTTTGTC	CAAACTCATC	AATGTATCTT	ATCATGTCTG	GTCGACTCTA	2500
2501	GATTCGAACT	CGAGGCCTGC	AGGGCGGCCG	CTTAATTAAT	TGATCCGGGT	2550
2551	TATTAGTACA	TTTATTAAGC	GCTAGATTCT	GTGCGTTGTT	GATTTACAGA	2600
2601	CAATTGTTGT	ACGTATTTTA	ATAATTCATT	AAATTTATAA	TCTTTAGGGT	2650
2651	GGTATGTTAG	AGCGAAAATC	AAATGATTTT	CAGCGTCTTT	ATATCTGAAT	2700
2701	TTAAATATTA	AATCCTCAAT	AGATTTGTAA	AATAGGTTTC	GATTAGTTTC	2750
2751	AAACAAGGGT	TGTTTTTCCG	AACCGATGGC	TGGACTATCT	AATGGATTTT	2800
2801	CGCTCAACGC	CACAAAACCTT	GCCAAATCTT	GTAGCAGCAA	TCTAGCTTTG	2850
2851	TCGATATTCG	TTTGTGTTTT	GTTTTGTAA	AAAGGTTTGA	CGTCGTTCAA	2900
2901	AATATTATGC	GCITTTGTAT	TTCTTTTCATC	ACTGTCGTTA	GTGTACAATT	2950
2951	GACTCGACGT	AAACACGTTA	AATAAAGCTT	GGACATATTT	AACATCGGGC	3000
3001	GTGTTAGCTT	TATTAGGCCG	ATTATCGTCG	TCGTCCCAAC	CCTCGTCGTT	3050
3051	AGAAGTTGCT	TCCGAAGACG	ATTTTGCCAT	AGCCACACGA	CGCCTATTAA	3100
3101	TTGTGTCGGC	TAACACGTCC	GCGATCAAAT	TTGTAGTTGA	GCTTTTTTGA	3150
3151	ATTATTTCTG	ATTGCGGGCG	TTTTTGGGCG	GGTTTCAATC	TAAGTGTGCC	3200
3201	CGATTTTAA	TCAGACAACA	CGTTAGAAAG	CGATGGTGCA	GGCGGTGGTA	3250
3251	ACATTTTACA	CGGCAAATCT	ACTAATGGCG	GCGGTGGTGG	AGCTGATGAT	3300
3301	AAATCTACCA	TCGGTGGAGG	CGCAGGCGGG	GCTGGCGGGC	GAGGCGGAGG	3350
3351	CGGAGGTGGT	GGCGGTGATG	CAGACGGCGG	TTTAGGCTCA	AATGTCTCTT	3400
3401	TAGGCAACAC	AGTCGGCACC	TCAACTATTG	TACTGGTTTC	GGGCGCCGTT	3450
3451	TTTGGTTTGA	CCGGTCTGAG	ACGAGTGCGA	TTTTTTTCGT	TTCTAATAGC	3500
3501	TTCCAACAAT	TGTTGTCTGT	CGTCTAAAGG	TGCAGCGGGT	TGAGGTTCCG	3550
3551	TCGGCATTGG	TGGAGCGGGC	GGCAATTCAG	ACATCGATGG	TGGTGGTGGT	3600
3601	GGTGGAGGCG	CTGGAATGTT	AGGCACGGGA	GAAGGTGGTG	GCGGCGGTGC	3650
3651	CGCCGGTATA	ATTTGTTCTG	GTTTAGTTTG	TTGCGGCACG	ATTGTGGGCA	3700
3701	CCGGCGCAGG	CGCCGCTGGC	TGCACAACGG	AAGGTCGTCT	GCTTCGAGGC	3750
3751	AGCGCTTGGG	GTGGTGGCAA	TTCAATATTA	TAATTGGAAT	ACAAATCGTA	3800
3801	AAAATCTGCT	ATAAGCATTG	TAATTTTCGCT	ATCGTTTACC	GTGCCGATAT	3850
3851	TTAACAACCG	CTCAATGTAA	GCAATTGTAT	TGTAAAGAGA	TTGTCTCAAG	3900
3901	CTCGGATCGA	TCCCGCACGC	CGATAACAAG	CCTTTTCATT	TTTACTACAG	3950
3951	CATTGTAGTG	GCGAGACACT	TCGCTGTCGT	CGCCTGATGC	GGTATTTTCT	4000
4001	CCTTACGCAT	CTGTGCGGTA	TTTCACACCG	CATACGTCAA	AGCAACCATA	4050
4051	GTACGCGCCC	TGTAGCGGCG	CATTAAGCGC	GGCGGTGTG	GTGGTTACGC	4100
4101	GCAGCGTGAC	CGCTACACTT	GCCAGCGCCC	TAGCGCCCGC	TCCTTTTCGT	4150
4151	TTCTTCCCTT	CCTTTCTCGC	CACGTTCCGC	GGCTTTCCCC	GTCAAGCTCT	4200
4201	AAATCGGGGG	CTCCCTTTAG	GGTTCCGATT	TAGTGCTTTA	CGGCACCTCG	4250
4251	ACCCCAAAAA	ACTTGATTTG	GGTGATGGTT	CACGTAGTGG	GCCATCGCCC	4300
4301	TGATAGACGG	TTTTTCGCCC	TTTGACGTTG	GAGTCCACGT	TCTTTAATAG	4350

56

57

4351	TGGACTCTTG	TTCCAAACTG	GAACAACACT	CAACCCTATC	TCGGGCTATT	4400
4401	CTTTTGATTT	ATAAGGGATT	TTGCCGATTT	CGGCCTATTG	GTTAAAAAAT	4450
4451	GAGCTGATTT	AACAAAAATT	TAACGCGAAT	TTTAACAAAA	TATTAACGTT	4500
4501	TACAATTTTA	TGGTGCACTC	TCAGTACAAT	CTGCTCTGAT	GCCGCATAGT	4550
4551	TAAGCCAGCC	CCGACACCCG	CCAACACCCG	CTGACGCGCC	CTGACGGGCT	4600
4601	TGTCTGCTCC	CGGCATCCGC	TTACAGACAA	GCTGTGACCG	TCTCCGGGAG	4650
4651	CTGCATGTGT	CAGAGGTTTT	CACCGTCATC	ACCGAAACGC	GCGAGACGAA	4700
4701	AGGGCCTCGT	GATACGCCCTA	TTTTTATAGG	TTAATGTCAT	GATAATAATG	4750
4751	GTTTCTTAGA	CGTCAGGTGG	CACTTTTTCG	GGAAATGTGC	GCGGAACCCC	4800
4801	TATTTGTTTA	TTTTTCTAAA	TACATTCAAA	TATGTATCCG	CTCATGAGAC	4850
4851	AATAACCCTG	ATAAATGCTT	CAATAATATT	GAAAAAGGAA	GAGTATGAGT	4900
4901	ATTCAACATT	TCCGTGTGCG	CATTATTCCC	TTTTTTGCGG	CATTTTGCCT	4950
4951	TCCTGTTTTT	GCTCACCAG	AAACGCTGGT	GAAAGTAAAA	GATGCTGAAG	5000
5001	ATCAGTTGGG	TGCACGAGTG	GGTTACATCG	AACTGGATCT	CAACAGCGGT	5050
5051	AAGATCCTTG	AGAGTTTTTC	CCCCGAAGAA	CGTTTTCCAA	TGATGAGCAC	5100
5101	TTTTAAAGTT	CTGCTATGTG	GCGCGGTATT	ATCCCCGTATT	GACGCCGGGC	5150
5151	AAGAGCAACT	CGGTCGCCGC	ATACACTATT	CTCAGAATGA	CTTGTTTGAG	5200
5201	TACTCACCAG	TCACAGAAAA	GCATCTTACG	GATGGCATGA	CAGTAAGAGA	5250
5251	ATTATGCAGT	GCTGCCATAA	CCATGAGTGA	TAACACTGCG	GCCAACTTAC	5300
5301	TTCTGACAAC	GATCGGAGGA	CCGAAGGAGC	TAACCGCTTT	TTTGACACAAC	5350
5351	ATGGGGGATC	ATGTAACTCG	CCTTGATCGT	TGGGAACCGG	AGCTGAATGA	5400
5401	AGCCATACCA	AACGACGAGC	GTGACACCAC	GTGCCTGTAG	CAATGGCAAC	5450
5451	AACGTTGCGC	AAACTATTAA	CTGGCGAACT	ACTTACTCTA	GCTTCCCCGC	5500
5501	AACAATTAAT	AGACTGGATG	GAGGCGGATA	AAGTTGCAGG	ACCACTTCTG	5600
5601	CGCTCGGCCC	TTCCGGCTGG	CTGGTTTATT	GCTGATAAAT	CTGGAGCCGG	5650
5651	TGAGCGTGGG	TCTCGCGGTA	TCATTGCAGC	ACTGGGGCCA	GATGGTAAGC	5700
5701	CCTCCCGTAT	CGTAGTTATC	TACACGACGG	GGAGTCAGGC	AACTATGGAT	5750
5751	GAACGAAATA	GACAGATCGC	TGAGATAGGT	GCCTCACTGA	TTAAGCATTG	5800
5801	GTAAGTGTCA	GACCAAGTTT	ACTCATATAT	ACTTTAGATT	GATTTAAAAC	5850
5851	TTCATTTTTA	ATTTAAAAGG	ATCTAGGTGA	AGATCCTTTT	TGATAATCTC	5900
5901	ATGACCAAAA	TCCCTTAACG	TGAGTTTTTC	TTCCACTGAG	CGTCAGACCC	5950
5951	CGTAGAAAAG	ATCAAAGGAT	CTTCTTGAGA	TCCTTTTTTT	CTGCGCGTAA	6000
6001	TCTGCTGCTT	GCAAAACAAA	AAACCACCGC	TACCAGCGGT	GGTTTGTTTG	6050
6051	CCGGATCAAG	AGCTACCAAC	TCTTTTTCCG	AAGGTAAC TG	GCTTCAGCAG	6100
6101	AGCGCAGATA	CCAAATACTG	TCCTTCTAGT	GTAGCCGTAG	TTAGGCCACC	6150
6151	ACTTCAAGAA	CTCTGTAGCA	CCGCCTACAT	ACCTCGCTCT	GCTAATCCTG	6200
6201	TTACCAGTGG	CTGCTGCCAG	TGGCGATAAG	TGGTGTCTTA	CCGGGTGGA	6250
6251	CTCAAGACGA	TAGTTACCGG	ATAAGGCGCA	GCGGTCCGGC	TGAACGGGGG	6300

57

58

6301	GTTCGTGCAC	ACAGCCCAGC	TTGGAGCGAA	CGACCTACAC	CGAACTGAGA	6350
6351	TACCTACAGC	GTGAGCTATG	AGAAAGCGCC	ACGCTTCCCG	AAGGGAGAAA	6400
6401	GGCGGACAGG	TATCCGGTAA	GCGGCAGGCT	CGGAACAGGA	GAGCGCACGA	6450
6451	GGGAGCTTCC	AGGGGGAAAC	GCCTGGTATC	TTTATAGTCC	TGTCGGGTTT	6500
6501	CGCCACCTCT	GACTTGAGCG	TCGATTTTTC	TGATGCTCGT	CAGGGGGGCG	6550
6551	GAGCCTATGG	AAAAACGCCA	GCAACGCGGC	CTTTTACGG	TTCCTGGCCT	6600
6601	TTTGCTGGCC	TTTGCTCAC	ATGTTCTTTC	CTGCGTTATC	CCCTGATTCT	6650
6651	GTGGATAACC	GTATTACCGC	CTTTGAGTGA	GCTGATAACG	CTCGCCGCAG	6700
6701	CCGAACGACC	GAGCGCAGCG	AGTCAGTGAG	CGAGGAAGCG	GAAGAGCGCC	6750
6751	CAATACGCAA	ACCGCCTCTC	CCCGCGCGTT	GGCCGATTCA	TTAATGCAG	6799

Seq ID No 33

CAGTGGATCTTGCTAGAGTTCTGCAGGATC

Seq ID No 34

GATCCTTGCAG AACTCTAGCAAGATCCACTG

Seq ID No 35 DNA sequence of #50391

CCAGCAGTGGCTCTTCCTGCTTCTGCAGGATC

Seq ID No 36 DNA sequence of #50392

GATCCTGCAGAAGCAGGAAGAGCCACTGCTGG

Seq ID No 37 Amino acid sequence of C3d-YL expressed in baculovirus/Sf9

1	Met	Ala	Leu	Trp	Met	Arg	Leu	Leu	Pro	Leu
10	Leu	Ala	Leu	Leu	Ala	Leu	Trp	Ala	Pro	Ala
21	Pro	Thr	Arg	Ala	Gly	Ser	Arg	Ser	Thr	Pro
31	Ala	Gly	Ser	Gly	Glu	Gln	Asn	Met	Ile	Gly
41	Met	Thr	Pro	Thr	Val	Ile	Ala	Val	His	Tyr
51	Leu	Asp	Gln	Thr	Glu	Gln	Trp	Glu	Lys	Phe
61	Gly	Ile	Glu	Lys	Arg	Gln	Glu	Ala	Leu	Glu
71	Leu	Ile	Lys	Lys	Gly	Tyr	Thr	Gln	Gln	Leu

58

59

81 Ala Phe Lys Gln Pro Ser Ser Ala Tyr Ala  
91 Ala Phe Asn Asn Arg Pro Pro Ser Thr Trp  
101 Leu Thr Ala Tyr Val Val Lys Val Phe Ser  
111 Leu Ala Ala Gln Leu Ile Ala Ile Asp Ser  
121 His Val Leu Cys Gly Ala Val Lys Trp Leu  
131 Ile Leu Glu Lys Gln Lys Pro Asp Gly Val  
141 Phe Gln Glu Asp Gly Pro Val Ile His Gln  
151 Glu Met Ile Gly Gly Phe Arg Asn Ala Lys  
161 Glu Ala Asp Val Ser Leu Thr Ala Phe Val  
171 Leu Ile Ala Leu Gln Glu Ala Arg Asp Ile  
181 Cys Glu Gly Gln Val Asn Ser Leu Pro Gly  
191 Ser Ile Asn Lys Ala Gly Glu Tyr Ile Glu  
201 Ala Ser Tyr Met Asn Leu Gln Arg Pro Tyr  
211 Thr Val Ala Ile Ala Gly Tyr Ala Leu Ala  
221 Leu Met Asn Lys Leu Glu Glu Pro Tyr Leu  
231 Gly Lys Phe Leu Asn Thr Ala Lys Asp Arg  
241 Asn Arg Trp Glu Glu Pro Asp Gln Gln Leu  
251 Tyr Asn Val Glu Ala Thr Ser Tyr Ala Leu  
261 Leu Ala Leu Leu Leu Leu Lys Asp Phe Asp  
271 Ser Val Pro Pro Val Val Arg Trp Leu Asn  
281 Glu Gln Arg Tyr Tyr Gly Gly Gly Tyr Gly  
291 Ser Thr Gln Ala Thr Phe Met Val Phe Gln  
301 Ala Leu Ala Gln Tyr Gln Thr Asp Val Pro  
311 Asp His Asp Leu Asn Met Asp Val Ser Phe  
312 His Leu Pro Ser Ser Gly Ser Glu Glu Phe

Seq ID No 38 Oligonucleotides for modification of bacterial vector pBroc413

TAT GAG ATC TCC CGG GGG ATC CTA GCG GCC GCT GCA

Seq ID No 39 Oligonucleotides for modification of bacterial vector pBroc413

GCG GCC GCT AGG ATC CCC CGG GAG ATC TCA

59

per the as 03913

000000

000000